Thyroid lesions simulating a squamoid pattern	Differential features

Pure squamous cells carcinoma	(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.

Primary head and neck squamous cell carcinoma	(i) Presence of in situ component in head and neck structures;(ii) features of “ab extrinseco” involvement of thyroid parenchyma; (iii) PAX8 is consistently negative.

Metastatic squamous cell carcinoma of the lung	(i) Presence of a lung nodule clinically detected;(ii) PAX8 is consistently negative.

Diffuse sclerosing variant of papillary thyroid carcinoma	(i) Abundant psammoma bodies;(ii) neoplastic cells retain nuclear features of PTC;(iii) immunoreactivity for thyroglobulin.

Mucoepidermoid carcinoma	(i) Combination of squamoid and mucinous components; (ii) thought to represent papillary carcinoma with extreme degree of squamous and mucinous metaplasia; (iii) low grade thyroid neoplasm.

Sclerosing mucoepidermoid carcinoma with eosinophilia	(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate).

CASTLE(carcinoma with thymus-like elements)	(i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences.


Terms of Delivery	Trichomonas vaginalis infection	P-value

Study group (positive cases)	Control group (negative cases)

No.	(%)	No.	(%)

Preterm birth	19	(54.28)	36	(13.58)	0.001

Full term birth	14	(40)	216	(81.5)	0.001

Post term birth	2	(5.7)	13	(4.9)	0.83

Total	35	(100)	265	(100)


Assumptions	Projected reduction in diabetes prevalence compared to no intervention

Moderate-risk [millions]	High-risk [millions]	Population [millions]	Combined [millions]

Base case assumptions:

Flat background diabetes incidence rate*	1.2 [3.1]	0.5 [1.2]	0.3 [0.7]	1.4 [3.6]

Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population

Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults

Adjustments to base case assumptions

Increasing background incidence rate*	1.4 [3.7]	0.5 [1.4]	0.3 [0.8]	1.6 [4.2]

Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population	2.5 [6.4]	1.0 [2.6]	0.3 [0.7]	2.7 [6.9]

Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population	0.6 [1.5]	0.3 [0.6]	0.3 [0.7]	0.8 [2.0]

Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults	1.2 [3.1]	0.5 [1.2]	0.2 [0.3]	1.1 [2.8]

Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults	1.2 [3.1]	0.5 [1.2]	0.6 [1.4]	1.6 [4.0]


	Target head angle (degrees)

	−80	−60	−40	−20	0	20	40

Pitch experiment

Qualitative descriptions	11	12	12	11	12	11	12

Switch‐press measures

DI, MV, PV, D	8	8	12	10	12	11	11

OF, in‐phase	7	3	10	9	10	2	4

OF, out‐phase	5	3	7	7	8	3	2

Roll experiment

Qualitative descriptions	N/A	N/A	10	11	11	11	10

Switch‐press measures

DI, MV, PV, D	N/A	N/A	10	11	11	11	10

OF, in‐phase	N/A	N/A	8	8	10	8	4

OF, out‐phase	N/A	N/A	5	7	8	8	6


	Ofloxacin	Injectable drugs	TotalResistance to either Fluoroquinolone or injectable drugsN (%)

	OfloxacinR, n (%)	KanamycinR, n (%)	CapreomycinR, n (%)

New MDR patients (n = 5)	0 (0)	0 (0)	0	0 (0)

Previously treated MDR patients (n = 33)	1 (3)	1 (3)	5 (15.2)	7 (21.2)

Total	1	1	5	7 (18.4)


Ectoparasite	 Postlactating females	 Nonreproductive females

	(n = 17)	(n = 97)

Spinturnix americanus	41.2%, 0.5 (0.7, 0–2)	38%, 0.7 (1.2, 0–5)

Myodopsylla insignis	47.1%, 1.1 (1.6, 0–5)	32%, 0.7 (1.3, 0–7)

Macronyssus crosbyi	0	7.2%, 0.1 (0.3, 0–2)

Cimex adjunctus	0	0

Androlaeps casalis	0	1%, 0.02 (0.2, 0–2)

Acanthophthirius spp.	0	1%, 0.02 (0.2, 0–2)

Any ectoparasite	76.5%, 1.6 (1.4, 0–5)	66%, 1.5 (1.7, 0–5)


Finding	Illustrating data

Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily	Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess’. (Mainstream consultant clinical specialist)

Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability	Case C: ‘We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around—in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available’. (Gynaecological oncologist in referring department)

‘In the end [our case to the commissioners] was more, ‘If you don't fund this there's going to be a great black hole that no-one can pick up’. I think that's how it was funded in the end’. (Lead nurse)

Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning	Case B: ‘The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no ‘must dos’ about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities’. (PCT former senior clinical manager)


No.	Themes	OSPE	OSCE	Frequency	Total

1.	Curriculum

 	 Syllabus	+	++	3	7

 	 Repetition	+++	+	4

2.	Skills assessment

 	 Practical/clinical skills	++	+++	5	12

 	 Concepts	+++	+	4

 	 Competence	++	+	3

3.	Confidence

 	 Confidence	++	+	3	6

 	 Comfort	++	+	3

4.	Fairness of exam	++	++	4	4

5.	Impact on learning

 	 Improved learning	+	+	2	5

 	 Future learning	+	++	3

6.	Stress

 	 Stress	++++	++++	8	17

 	 Time	++++++	+++	9

7.	Organisation of exam	++	++	4	4

8.	Examiners’ calibration	+++	++++++++	8	11


	Intention to treat	Modified intention to treat

	Antibiotic treatmentn = 22	No antibiotic treatmentn = 36	P value	Antibiotic treatmentn = 18	No antibiotic treatmentn = 26	P value

Tracheostomy	5 (22)	5 (13)	>0.999	5 (27)	5 (19)	0.716

Corticosteroid use	8 (36)	19 (52)	0.283	6 (33)	13 (50)	0.359

Septic shock	1 (4)	7 (19)	0.134	1 (5)	5 (19)	0.375

ICU-acquired infections other than VAT and VAPa	7 (31)	18 (50)	0.274	6 (33)	13 (50)	0.359

 Bacteremia	6 (27)	13 (36)	0.572	5 (27)	8 (30)	>0.999

 Urinary tract infection	2 (9)	5 (13)	0.698	2 (11)	5 (19)	0.682

 Others	2 (9)	2 (5)	>0.999	2 (11)	2 (7)	>0.999

Total duration of antibiotic treatment, days	25 ± 14	19 ± 15	0.149	24 ± 15	17 ± 15	0.104

Antibiotic treatment before VAT	18 (81)	29 (80)	>0.999	15 (83)	23 (88)	0.676

Antibiotic treatment during the 8 days following random assignment	22 (100)	21 (58)	<0.001	18 (100)	10 (38)	<0.001

Reasons for antibiotic treatment during the 8 days following random assignment

 VAT	22 (100)	0 (0)	<0.001	18 (100)	0 (0)	<0.001

 VAP	0 (0)	15 (41)	<0.001	0 (0)	10 (38)	0.003

 Other infections	0 (0)	6 (16)	0.073	0 (0)	0 (0)	NA

Antibiotic treatment after day 8 post-random assignment	6 (27)	8 (22)	0.756	3 (16)	5 (19)	>0.999


	Response rate	NR

	Prosody+	Prosody−	Prosody+	Prosody−

Healthy controls (CI 95%)	96 ± 4 (94, 98)	84 ± 7 (81, 87)	3 ± 4(2, 2)	10 ± 7(7, 14)

Patients with schizophrenia (CI 95%)	78 ± 16 (70, 86)	58 ± 19 (49, 67)	22 ± 17 (14, 30)	37 ± 20 (28, 47)


Clinical trials	Interventions	URL

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study	Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)	https://ClinicalTrials.gov/show/NCT01583842

European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)	Drug: chemotherapy	https://ClinicalTrials.gov/show/NCT01728155

Phase II Study of Proton Radiation Therapy for Neuroblastoma	Radiation: proton beam radiation therapy	https://ClinicalTrials.gov/show/NCT02112617

Immunomonitoring of Children With Neuroblastoma	Immunological analyses	https://ClinicalTrials.gov/show/NCT01295762

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma	Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH	https://ClinicalTrials.gov/show/NCT00911560

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma	Laboratory biomarker analysis; cytology specimen collection procedure	https://ClinicalTrials.gov/show/NCT00904241

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma	Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide	https://ClinicalTrials.gov/show/NCT01467986

Study of DNA in Blood Samples From Patients With Neuroblastoma	Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis	https://ClinicalTrials.gov/show/NCT00898391

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)	Device: FLT-PET	https://ClinicalTrials.gov/show/NCT01308905

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma	Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole	https://ClinicalTrials.gov/show/NCT02075177

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma	Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses	https://ClinicalTrials.gov/show/NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma	Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin	https://ClinicalTrials.gov/show/NCT02100930

Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma	Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine	https://ClinicalTrials.gov/show/NCT02163356

Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma	Biological: activated T lymphocyte	https://ClinicalTrials.gov/show/NCT01802138

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN	Genetic: iC9-GD2 T-cell lymphocytes – frozen cellsGenetic: iC9-GD2 T-cell lymphocytes – fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab	https://ClinicalTrials.gov/show/NCT01822652


Capacity areas/skills for HPSR+A	Proportion of staff requiring additional training (n = 123), n (%)

HPSR+A technical skills and conceptual underpinnings,

 e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching	101 (82.0)

HPSR+A research and writing

 Writing research methodologies	84 (68.0)

 Writing briefing notes for politicians, policymakers, external funders and donors

80 (65.0)

 Writing papers for academic journals	78 (63.0)

Management and administration

 Leadership	92 (75.0)

 Effective networking	94 (76.0)

Financial and information management

 Identifying and applying for external funding sources	95 (77.0)

 Creating and managing effective and efficient financial reporting systems	91 (74.0)

 Creating and managing effective internal information systems	101 (82.0)


Treatment	Dose mg kg−1	Cotton pellet granuloma

Weight of pellets Mean ± SEM

Control	0.3 mL	51.73 ± 2.35

Indomethacin	10	19.82 ± 2.52 (61.68)b

EEDR	100	37.24 ± 2.00 (27.99)NS

EEDR	200	30.85 ± 3.72 (40.36)b

EEDR	400	29.77 ± 3.76 (42.44)a


Successful Aging Approach	Definition	References

Biomedical	Absence of multi-morbidity	[6]

Psycho-Cognitive	Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience	[3,12,14,38]

Lay View Approach	Presence of well-being, good self perceived health	[8,12]

Combined Approach	Optimal functioning	[6,12]


Country and Year	Criteria used for identifying asymptomatic malaria cases	Study subjects, sample size	Follow-up protocol and duration	Ref.

Africa

Gabon, 2003	No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during follow-up.	Children6 months to 10 years, N = 60	Examined once daily for 7 days thereafter, once every 2 days	[37]

Tanzania, 2006	Presence of P. falciparum on blood smear, axillary temperature of < 37.5°C, and no other symptoms or signs of malaria	Children4-59 months,N = 127	No follow-up.	[33]

South America

Brazilian Amazon, 2002	Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR.	All age groups,N = 172	Follow-up to day 10 and 60.	[21]

Colombia, 2008	Presence of microscopic asexual parasite stages of P. falciparum, P. vivax or P. malariae or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period.	Individuals2-78 years,N = 21	Follow-up on days 14 and 28.	[19]

Asia

Papua, 2003	No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both P. falciparum and P. vivax positive individuals	Adults> 16 years,N = 105	Supervised overnight at local health center. A third axillary temperature was recorded the following morning.	[38]

Indonesia, 2010	Presence of asexual P. falciparum or P. vivax parasitemia in the absence of fever (temperature ≤ 37.9°C) and of clinical signs or symptoms suggestive for malaria or another infectious disease.	Children5-15 years,N = 381	No follow-up.	[27]


Samples	Inhibition zones ± (mm)1

E. coliCCMB261	S. aureus CCMB262	S. aureus CCMB263	P. aeruginosaCCMB268	C. albicansCCMB286	C. parapsilosisCCMB288

L. alnifolia leaves	R	10.2 ± 1.3	10 ± 0.5	R	R	R

L. alnifolia stems	R	12.3 ± 1.0	13.9 ± 0.8	R	R	R

L. alnifolia flowers	R	8.4 ± 0.9	R	R	R	6.9 ± 0.1

L. origanoides leaves	R	13.0 ± 0.5	12.0 ± 0.9	R	11.7 ± 0.4	7.1 ± 0.4

L. origanoides stems	R	R	R	R	R	R

L. thymoides  leaves	R	11.2 ± 1.0	9.7 ± 1.3	R	R	R

L. thymoides stems	R	8.7 ± 0.6	R	R	R	R

L. thymoides  flowers	R	8.5 ± 1.5	R	R	R	R

Cloramphenicol2	15.8 ± 1.7	22.6 ± 2.2	R	8.5 ± 0.9	—	—

Nystatin3	—	—	—	—	17.5 ± 0.9	16.6 ± 0.9


Characteristics	n (N = 157)	%

Age	<19 years	3	1.9

20–24 years	104	66.3

25–29 years	47	29.9

>30 years	3	1.9

Gender	Male	67	42.7

Female	88	56.1

Marital status	Divorced	2	1.3

Not Married	151	96.2

Married	4	2.5

Educational level	Bachelor degree	120	76.4

Master degree	14	8.9

Doctor degree	23	14.6

Work experience in the health sector	<6 months	52	33.1

6–12 months	53	33.8

12–24 months	44	28.0

24–36 months	3	1.9

>36 months	5	3.2

Hours worked daily	<6 h	9	5.7

6–8 h	86	54.8

8–10 h	41	26.1

10–12 h	18	11

>12 h	3	1.9

Night shifts/week	<1	34	21.7

1	71	45.2

>1	46	29.3

0	6	3.8

Clinic service visits/week	<5	99	63.1

5–9	19	12.1

10–14	7	4.5

15–19	6	3.8

>20	26	16.6

Discharges/month	<5	49	31.2

5–9	35	22.3

10–14	24	15.3

15–19	15	12.1

>20	30	19.1


Neonatal characteristic 	Newborn-monotherapy dyadsMean (SE) or n (%)	Newborn-triple therapy dyadsMean (SE) or n (%)	p value

Gender

 Male	45 (53%)	18 (49%)	NS

Gestational age (weeks)∗	38 (0.2)	37 (0.5)	<0.01

Birth weight (g)∗	3079 (63)	2864 (96)	NS

Small for gestational age	18 (21%)	3 (8%)	NS

Toxicology screen

 Positive	10 (12%)	23 (62%)	<0.05

NICU admission	19 (22%)	20 (54%)	<0.01

Length of stay in hospital (days)∗	3 (0.5)	8 (2)	<0.05

CPS involved	15 (18%)	26 (70%)	<0.01


ARV site	Total number of patients

Thamaga primary hospital	1646

Nkoyaphiri clinic	1726

Gabane clinic	392

Thamaga clinic	114

Mmankgodi clinic	70

Kopong clinic	200

Mmopane clinic	120

Total	4268


Group	No. mice	Vaccine and administration	Anti‐HCV Abs	Days post‐prime

Prime	2xboost	0	14	28	42

				Serum IgM	0/5	0/5	0/5	0/5

0	5			Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

		im	Feeding	Serum IgM	0/5	5/5	5/5	5/5

1	5	HEK293T‐E1E2	Lettuce E1E2	Serum IgG	0/5	0/5	0/5	4/5

				Faeces IgA	0/5	4/5	4/5	4/5

		Feeding		Serum IgM	0/7	0/7	1/7	2/7

2	7	Lettuce‐E1E2∆N6		Serum IgG	0/7	0/7	0/7	0/7

				Faeces IgA	0/7	3/7	3/7	3/7

		Feeding		Serum IgM	0/5	0/5	1/5	1/5

3	5	Lettuce‐E1E2		Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

4	5	im	im	Serum IgM	0/5	ND	5/5	5/5

		HEK293T‐E1E2	HEK293T‐E1E2	Serum IgG	0/5	ND	5/5	5/5

				Faeces IgA	ND	ND	5/5	5/5


species	factors associated with chick-a-dee call variation	references

black-capped chickadee Poecile atricapillus	species	[48,68–70]

flock	[71,72]

individual	[73]

predator	[74–76]

boreal chickadee P. hudsonicus	individual	[77]

chestnut-backed chickadee P. rufescens	individual	[78]

Carolina chickadee P. carolinensis	species	[48]

local population	[79]

individual	[80]

energetic state	[81]

predator	[82–85]

food	[87,88]

flight	[59,82]

Mexican chickadee P. sclateri	individual	[89]

mountain chickadee P. gambeli	species	[68,69]

individual	[90]

flight	[91]

tufted titmouse Baeolophus bicolor	individual	[92]

predator	[83,93,94]

crested tit Lophophanes cristatus	proximity to cover	[95,96]

willow tit Poecile montana	predator	[97]


 	n	%*

Number of patients	635

Median age at time of VIT-initiation (years) (range)	39	(5–77)

Male/female	322/313

Results of allergy testing

 Vespula (vulgaris/germanica) mono sensitization	251	39.5

 Honey bee (Apis mellifera) mono sensitization	33	5.2

 Double sensitization	351	55.3

Severity of anaphylaxis to pre-VIT index field sting

 Large local reaction	8	1.3

 Grade I (mild)	171	26.9

 Grade II (moderate)	321	50.6

 Grade III (severe)	135	21.3

Treatment course

 Mean duration of VIT (years) (range)	3.9	(3–13)

 Mean observation time after VIT (years) (range)	7.0	(0–17)


Disease	No. withdrawals/treated patients	Inefficacy or loss of efficacy	Adverse event	Persistent remission	On-demand treatment	Patient request	Switch to canakinumab

AOSD	20/35	14	3	1	0	2	2

Gout	18/28	0	0	17	1	0	0

SJIA	16/26	7	3	5	0	1	6

CAPS	11/21	1	1	1	0	8	3

MKD	7/10	2	2	0	0	3	4

FMF	6/13	1	3	0	1	1	3

SAPHO	7/9	5	2	0	0	0	0

Schnitzler’s syndrome	3/7	1	2	0	0	0	1

Spondylo arthritis	5/5	2	3	0	0	0	0

Vasculitis	2/4	2	0	0	0	0	2

Chondro calcinosis	2/4	1	0	1	0	0	0

TRAPS	1/3	1	0	0	0	0	0

GPP	2/3	1	0	1	0	0	0

Polychondritis	1/3	1	0	0	0	0	0

NAPS12	2/2	2	0	0	0	0	0


Patients	NMO/NMOSD	MS

Number	20	8

Age	49.4 ± 3.9	43.0 ± 4.8

Male:Female	4:16	4:4

Disease duration	8.1 ± 2.0	9.9 ± 3.7

Relapses in the last 2 years	1.2 ± 0.3	2.3 ± 0.5

EDSS∗ score in disease remission	3.3 ± 0.5	4.1 ± 1.0


% Change in relative probability of delivery with a 5-min increase in travel timea

Delivery at any facility	−30.0

Public facility delivery	−28.2

Private facility delivery	−32.9

NGO facility delivery	−28.6


Cell Types	Species/Cell Lines	Melotonin Effects	Receptor Types	Melatonin Concentrations	References

Leydig cell	mouse	Inhibition of steroid production	Inhibition of StAR protein expression 	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	MA-10		Inhibition of progesterone production	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	Rat	Inhibition of steroid production	Inhibition of androgen production 	-	4 pM to 4 μM	[40]

			Inhibition of GnRH-dependent intracellular Ca2+release 	-	0.2 pM	[46]

	Hamster	Inhibition of steroid production	Stimulation of CRH production	Mt1	1 and 10 μM	[12,54]

			Stimulation of tyrosine phosphatases activity	Mt1	1 and 10 μM	[54]

			Inhibition of erk and jnk phosphorylation	Mt1	1 and 10 μM	[54]

			Downregulation of c-fos and c-jun expression	Mt1	1 and 10 μM	[54]

			Inhibition of StAR, Hsd3b and Hsd17b3 expression	Mt1	1 and 10 μM	[12,54]

			Inhibition of cAMP generation 	Mt1	1 μM	[12]

			Inhibition of androgen production	Mt1	100 pM to 1 μM	[12,54]

Sertoli cell	Rat	Regulation of energy metabolism	Inhibition of basal lactate production	Mt1 and Mt2	1 mM	[33]

			Upregulation of the insulin-stimulated lactate generation	Mt1 and Mt2	1 mM	[33]

			Stimulation of GLUT1 protein expression and glucose consumption		1 mM	[33]

			Inhibition of LDH protein expression and activity	Mt1 and Mt2	1 mM	[33]

			Stimulation of acetate production		1 mM	[33]

		Prevention of testicular damage	Regulation of intracellular redox state	Mt1 and Mt2	1 mM	[33]

	Hamster	Prevention of testicular damage	Stimulation of the responsiveness to FSH during testicular development	-	25 μg daily injection (1 to 15 wk)	[24]

	Bovine	Stimulation of cell growth/proliferation	Downregulation of mRNA P21 expression	Mt1 and Mt2	0.3 to 1 nM	[59]

		Regulation of spermatogenesis	Upregulation of Cyclin D1, Cyclin E, Pdgfa, Dhh, Ocludin and Claudin expression	Mt1 and Mt2	0.3 to 1 nM	[59]

	Goat	Stimulation of SSCs proliferation	Stimulation of GDNF production	Mt1 and Mt2	1 nM and 1 μM	[73]


Demographics

Mean age, years (range)	32 (11–55)

Male : female	43 : 8

Transfusion requirements, units (range)	7 (3–12)


Item	Component

1	2

Pain	0.555	−0.162

Shortness of breath	0.497	−0.318

Weakness or lack of energy	0.547	−0.379

Nausea	0.251	−0.779

Vomiting	0.196	−0.694

Poor appetite	0.398	−0.236

Constipation	0.305	−0.001

Mouth problems	0.558	−0.305

Drowsiness	0.433	−0.320

Poor mobility	0.672	−0.050

Itching	0.361	−0.317

Difficulty sleeping	0.506	−0.386

Restless legs	0.150	−0.223

Feeling anxious	0.537	−0.303

Feeling depressed	0.586	−0.218

Changes in skin	0.329	−0.345

Diarrhoea	0.187	−0.486

Muscle cramps	0.229	−0.358


Measurement	Location	Data points	Sampling rate

Parameter	Method	Performed by	Laboratory	Office	d-1 (overall)	s-1

Physiological

 Sitting time	IPAQ-long	questionnaire - interview	x		1 (4)	n.a.d

 Physical activity	IPAQ-long	questionnaire - interview	x		1 (4)	n.a.d

 Mental workload	NASA-TLX	questionnaire	x		1 (4)	n.a.d

 Salivary cortisol	saliva collection	Salivette + cortisol ELISA	xa		8 (32)	n.a.d

 Heart-rate	ECG	ECG recorder	xb		n.a.c	250

 Body movements	acceleration	ECG recorder	xb		n.a.c	250

Cognitive

 Working speed	text editing task	computer software (matlab)	x		5 (20)	>1000

 Reaction time	Stroop-test	computer software (matlab)	x		5 (20)	>1000

 Attention	d2R-test	test sheet	x		5 (20)	n.a.d

Office based

 Body postures	logging tool	computer software (C#)		x	n.a.c	>1000

 Postural changes	logging tool	computer software (C#)		x	n.a.c	>1000


Patient type	RCTs n (%)

Medical/Surgical	106 (43)

Medical only	56 (23)

 Bronchiolitis	16 (6)

 Sepsis/Shock	13 (5)

 Asthma	8 (3)

 Other medical	19 (8)

Surgical only	60 (24)

Cardiac surgery	46 (19)

Noncardiac surgery	14 (6)

Trauma/Burns only	26 (10)

 Traumatic brain Injury	13 (5)

 Burns	13 (5)


	Neoadjuvant (n = 80)	Adjuvant (n = 90)	P

PHS (days)	11 (7–33)	11 (5–51)	0.920a

PHS with complications (days)	15	17	0.503b

PHS without complications (days)	11	11	0.972a

Patients with complications	15 (18.8%)	20 (22.2%)	0.704

Non-surgical complications

Pneumonia	1 (1.3%)	3 (3.3%)	0.623

Pleural effusion	0 (0.0%)	2 (2.2%)	0.499

Gastrointestinal motility disorders	3 (3.8%)	3 (3.3%)	1.000

Thrombosis	1 (1.3%)	1 (1.1%)	1.000

Renal dysfunction	1 (1.3%)	1 (1.1%)	1.000

Catheter-related sepsis	1 (1.3%)	0 (0.0%)	0.471

Other (urinary, thrombocytopenia)	1 (1.3%)	4 (4.4%)	0.372

Surgical complications

Anastomotic leakage	0 (0.0%)	2 (2.2%)	0.499

Surgical site infection	5 (6.2%)	6 (6.7%)	1.000

Postoperative hemorrhage	3 (3.8%)	1 (1.1%)	0.343

Wound dehiscence	0 (0.0%)	2 (2.2%)	0.499

Lymphorrhea	2 (2.5%)	1 (1.1%)	0.602

Ileus	0 (0.0%)	1 (1.1%)	1.000

Biliary fistula	1 (1.3%)	0 (0.0%)	0.471


 	Pre-supplementation	Post-supplementation

Measure	Subjects reporting GIT symptoms post-supplement (mean)	Subjects GIT symptom free post-supplement (mean)	P value	Subjects reporting GIT symptoms post- supplement (mean)	Subjects GIT symptom free post-supplement (mean)	P value

General health indices

 Neurological index	1.3	0.5	< 0.004	1.0	0.4	ns

Chalder fatigue scale

 Total fatigue scores	14.2	11.8	ns	12.6	8.9	ns

Amino acids

 (Relative % abundance)

 Asparagine	6.60%	4.78%	< 0.03	6.11%	4.89%	ns

 Hydroxylysine	1.62%	1.15%	< 0.05	1.72%	1.32%	ns

 Hydroxyproline	0.58%	0.34%	< 0.04	0.65%	0.52%	ns


Municipality	% Speaking indigenous language	% Speaking Zapotec monolingual	% Speaking Zapotec monolingual	% Of 15 year-old or older who read and write in Spanish	Average number of years in school	% Of the population engaged in primary production activities

 	Year 2000	Year 2000	Year 1950	Year 2000	Year 2000	Year 2000

Juchitán de Zaragoza	70.01	8.81	27.26	52.11	6.26	13.89

San Blas Atempa	92.76	24.87	72.08	39.95	3.56	33.79

Santa María Xadani	97.71	34.07	83.33	32.05	3.36	35.01


 	Before	After

N	39249	39249

Analgesics (N, %)

 Represcribed pregabalin use	—	4009 (10.2)

 1-2-line drugs	5416 (13.8)	3213 (8.2)

Continued use	—	1761 (4.5)

New use	—	1348 (3.4)

Changed/added drugs	—	104 (0.3)

 TCAs	837 (2.1)	448 (1.1)

 Gabapentin	355 (0.9)	197 (0.5)

 Neurotropin	3775 (9.6)	2106 (5.4)

 Duloxetine	501 (1.3)	455 (1.2)

 Mexiletine	310 (0.8)	221 (0.6)

 Opioids	8171 (20.8)	5954 (15.2)

Continued use	—	1580 (4.0)

New use	—	2894 (7.4)

Changed/additions of drugs/route	—	1480 (3.8)

 Oral opioids	5008 (12.8)	3350 (8.5)

Continued use	—	1358 (3.5)

New use	—	1649 (4.2)

Changed/added drugs	—	160 (0.4)

Changed/additions of route	—	183 (0.5)

 Nonoral opioids	4737 (12.1)	3368 (8.6)

Continued use	—	702 (1.8)

New use	—	1465 (3.7)

Changed/added drugs	—	527 (1.3)

Changed/additions of route	—	674 (1.7)

 Weak opioids	3238 (8.2)	2377 (6.1)

Continued use	—	710 (1.8)

New use	—	1444 (3.7)

Changed/added drugs	—	76 (0.2)

Changed/additions of the strength	—	147 (0.4)

 Strong opioids	5928 (15.1)	3963 (10.1)

Continued use	—	1010 (2.6)

New use	—	1644 (4.2)

Changed/added drugs	—	1062 (2.7)

Changed/additions of the strength	—	247 (0.6)


Characteristic	n = 133

Age (years)a	67.2 ± 9.4

Sex

 Male	77

 Female	56

Diagnosis

 Pancreatic carcinoma	49

 Cholangiocarcinoma	49

 Ampullary carcinoma	13

 Intraductal papillary mucinous neoplasm	6

 Neuroendocrine tumor	5

 Others	11

Total bilirubin (mg/dL)a	4.9 ± 5.5

Preoperative biliary drainage

 Yes	93

 No	40

Operation

 PD	20

 SSPPD	41

 PPPD	72

Operation time (min)a	454.3 ± 99.8

Blood loss (mL)a	990.6 ± 701.3

Transfusion

 Yes	33

 No	100


Measure	DF	F	P

DASS-depression	1.61	.24	.79

DASS-anxiety	1.60	1.72	.19

DASS-stress	1.61	2.05	.14

DASS-total	1.60	1.39	.26

FS (Wellbeing)	1.45	.57	.57


Comparison	P-value	Comparison	P-value

Breast/Colon	0.0001	Colon/SCC	0.135

Breast/SCC	0.114	Colon/KA	0.027

Breast/KA	0.0001	KA/SCC	0.0001

Breast (T)/Breast (M)	0.723	MSI-High/MSI-Low	0.443


	DL-CNN vs RS1	AI-CALS vs RS1	DL-CNN vs RS2	AI-CALS vs RS2

Average minimum distance AVDIST

 Pre-treatment	4.8 ± 1.8mm	5.3 ± 2.7mm	4.9 ± 3.4mm	4.5 ± 1.9mm

 Post-treatment	4.3 ± 1.7mm	4.4 ± 1.8mm	4.7 ± 3.1mm	4.9 ± 3.7mm

 Both	4.6 ± 1.8mm	4.8 ± 2.3mm	4.8 ± 3.2mm	4.7 ± 2.9mm

Jaccard index JACCARD3D

 Pre-treatment	45.3 ± 8.5%	42.5 ± 14.1%	46.8 ± 9.3%	42.8 ± 12.5%

 Post-treatment	29.8 ± 17.7%	32.9 ± 14.8%	28.8 ± 19.7%	28.6 ± 18.2%

 Both	37.5 ± 15.8%	37.7 ± 15.2%	37.8 ± 17.8%	35.7 ± 17.1%


	Daily Cannabis Users	Cannabis Non-Users

Sample Size (N)	243	244

Gender	81% male; 19% female	51% male; 49% female

Average Age*	M = 37.8, SD = 13.3	M = 28.2, SD = 11.0

Maximum Income Bracket**	M = $44,431, SD = $23,027	M = $39,640, SD = $24,159


Causative factors	Numbers

Antenatal	38 (11.7 %)

Intrapartum	220 (67.9 %)

 Placental abruption	87

 Cord prolapse	16

 Uterine rupture	15

 Maternal hypoxic event	8

 Fetal exsanguination	8

 Clinical CAM (Group I )	19

 Non clinical CAM (Group II)	67

Perinatal	8 (2.5 %)

 Fetal central nervous system or systemic infection	8

Miscellaneous	58 (17.9 %)

 Suspected CAM	54

 Unknown causes	4

Total	324


Interactions	Patientsn = 624n (%)

Potential drug-drug interactions	492 (78.8)

Number of potential drug-drug interactions*

 1	154 (24.7)

 2	92 (14.7)

 3–4	154 (24.7)

 ≥ 5	92 (14.7)

Type D	24 (3.8)

 ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation)	11 (1.8)

 NSAID*+ Methotrexate	5 (0.8)

 NSAID* +anticoagulants (or glucocorticoids)	5 (0.8)

 β blocking agents + Verapamil (or Fluoxetin)	3 (0.4)

Type C	468 (75.0)

 ACE* inhibitors + NSAID*	252 (40.4)

 NSAID*+ low dose ASA*	212 (34.0)

 NSAID*+ sulfonylureas	128 (20.5)

 ACE* inhibitors + low dose ASA*	130 (20.8)

 β blocking agents + NSAID*	107 (17.1)

 NSAID* + Diuretics	105 (16.8)

 ACE* inhibitors + glybenclamide	68 (10.9)

 NSAID*+ other NSAID*	51 (8.2)

 ACE* inhibitors + thiazide diuretics	47 (7.6)

 Pravastatin + bezafibrate	35 (5.6)

 Pentoxiyilline + antihypertensives	37 (5.9)

 Metformin+ ranitidine	40 (6.5)

 Glibenclamide + antimycotics or cotrimoxazole	24 (3.9)

 Furosemide + ACE* inhibitors	21 (3.4)

 ACE* inhibitors + antiacids	19 (3.1)

 Alendronate + NSAIDs*	18 (2.9)

 Insulin + antihypertensive	18 (2.9)

 Pentoxifylline + hypoglycemic agents	14 (2.2)

 Acetaminophen + carbamazepin	14 (2.2)

 Ranitidine + azole type of antimycotics	11 (1.8)

 Others	61 (9.4)

Potential drug-disease interactions	400 (64.1)

Number of potential drug-disease interactions

 1	346 (55.4)

 ≥ 2	54 (8.7)

NSAIDs* in patients with hypertension and/or chronic heart failure	384 (61.5)

β blocking agents in patients with diabetes mellitus	31 (5.0)

NSAIDs* in patients with chronic renal insufficiency	18 (2.9)

NSAIDs* in patients with previous peptic ulcer	8 (1.3)

Thiazides diuretics in patients with gout	7 (1.1)

Metformin in patients with chronic renal insufficiency or congestive heart failure	6 (1.0)

β blocking agents in patients with peripheral vascular disease	4 (0.6)

β blocking agents in patients with asthma/COPD*	3 (0.5)

Others	5 (1.0)


District	Number	Percent

Gulu

Total anaemia	117	32.9

Mild anaemia	82	23.0

Moderate anaemia	32	9.0

Severe anaemia	3	0.8

Hoima

Total anaemia	47	12.1

Mild anaemia	35	9.0

Moderate anaemia	10	2.5

Severe anaemia	2	0.5


Gene type	Number of genes*	Differentially expressed*	Enrichment p-value**	Enrichment status+

Housekeeping	3292	29	1.60E-13	Depleted

Weak promoter	5262	118	0.07	Depleted

Narrow promoter	930	43	1.20E-04	Enriched

Broad promoter	1279	51	9.50E-04	Enriched

Bivalent	3400	166	4.90E-18	Enriched


	CT	MRI	DSA

unenhanced	enhancement	unenhanced	Gd-DTPA-enhanced	enhancement

shape	border	density	Arterial phase	Venous phase	shape	border	T1WI	T2WI	DWI	Arterialphase	Venousphase	Delayphase

case1	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case2	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case3	M-R	well	hypo	hetero	moderate	Lob	well	hypo	hyper	hyper	hetero	moderate	mild	hyper

case4	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case5	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case6	M-O	well	hypo	hetero	moderate	M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case7	M-O	well	hetero, hypo	hetero	moderate	M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case8	S-R	well	hypo	homo	mild	nodule	well	hypo	hyper	hyper	homo	moderate	mild	hyper

case9						M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case10						M-N	well	hypo	hyper	sig. Hyper	hetero	mild	mild	hyper

case11						Irr	well	hetero	hyper	hyper	hetero	hetero	hetero	hetero


 	Outlet type

Anti-malarials	Private	Not-for-profit

 	Median price (range) USD	Median price ratio	Median price (range) USD	Median price ratio

AL*	0.94 (0.63-1.25)	1.88	0.75 (0.63-1.00)	1.5

Other forms of ACT**	6.0 (1.88-10.63)	12	2.5 (1.88-3.13)	5

Quinine*	1.0 (0.75-1.25)	1.33	0.75 (0.63-1.13)	1


VariableOral morphine equivalents, mg	Pre Group(n = 276)	ERAS Group(n = 96)	p-value

Total Opioid use, Mean (SD)	163.8 (73.2)	111.4 (46.0)	< 0.001*

Intraop Opioid use, Mean (SD)	93.6 (33.8)	73.4 (29.8)	< 0.001*

PACU Opioid use, Mean (SD)	36.7 (30.8)	15.4 (19.3)	< 0.001*

Hospital Floor Opioid use, Mean (SD)	33.4 (44.5)	22.6 (19.3)	0.001*


Lichen species	Phenolics contentμg of pyrocatechol equivalent	Flavonoid contentμg of rutin equivalent

C. furcata	12.95 ± 1.065	10.55 ± 1.099

L. atra	73.02 ± 1.275	54.77 ± 1.231

L. muralis	43.19 ± 1.085	34.56 ± 1.074


Disease		Days after inoculation

		8	11	14	17	20

Cercospora leaf spot	Overall accuracy [%]	98.90	89.01	96.58	98.73

	Kappa coefficient	0.99	0.53	0.92	0.98

	Diseased leaf area [%]	0	6.56	7.61	20.92

Powdery mildew	Overall accuracy [%]	94.34	96.79	97.23	90.18

	Kappa coefficient	0.88	0.91	0.95	0.84

	Diseased leaf area [%]	14.40	19.37	41.94	50.04

Sugar beet rust	Overall accuracy [%]					61.70

	Kappa coefficient					0.56

	Diseased leaf area [%]					2.89


S. No.	Name of the seed	Hot water extraction (%)	Pressurized hot water extraction (%)	Solvent extraction (%)

1.	Syzygium cumini	16.07	49.24	78.14

2.	Citrus sinensis	19.80	74.79	75.65

3.	Mangifera indica	59.54	84.76	65.17

4.	Vitis vinifera	68.87	79.86	83.31

5.	Manilakara zapota	44.72	81.59	81.24

6.	Artocarpus heterophyllus	40.92	87.52	82.68


		Male

		Heinz 1706	LA716	Periclinal 1

Female	Heinz 1706	Yes	Yes	Yes

LA716	No	Yes	No

Periclinal 1	No	Yes	No


Province	District	Village	No. of larvae

Nangarhar	Behsood	Banaghar, Samarkhel, Saracha	200

Jalalabad	Bagrami	200

Kama	Banajur, Sabirlalay, Sangarsary	200

Kunar	Chawkay	Babur	200

Nurgal	Nurgal	200

Assadabad	Asadabad	200


PCR target	Midguts from mosquitoes fed on gametocyte cultureMean Cp (95% CI)	Midguts with microscopy-confirmed P. falciparum oocystsMean Cp (95% CI)

EHV	24.75(24.68–24.82)	24.14(23.68–24.61)

RPS7	22.85(22.68–23.02)	23.03(22.0–24.07)


	Proton concordant & HiSeq discordant	HiSeq concordant & Proton discordant	All concordant	Both discordant

Total	HiSeq = Proton	All discordant

Average	64	1849	76945	216	202	14

%CV	19.6	55.6	1.24	4.23	5.51	31.6

Common	1	43	66472	80	67	1


Label claim Mg/tablet	Amount added %	Total amount added (mg)	Amount recovered* (mg) ± SD	% Recovery ± SD (n = 3)

Risperidone	50	1	0.99 ± 0.02	99.66 ± 1.79

2	100	2	2.01 ± 0.02	100.21 ± 1.11

	150	3	3.01 ± 0.04	100.31 ± 1.46


EcoRI primers	MseI primers

Name	Sequence	Name	Sequence

E1	AAC	M1	CAA

E2	AAG	M2	CAC

E3	ACA	M3	CAG

E4	ACT	M4	CAT

E5	ACC	M5	CTA

E6	ACG	M6	CTC

E7	AGC	M7	CTG

E8	AGG	M8	CTT


Property	PRD File	FAM File

Identifier	PRD_######, e.g., PRD_000001	FAM_######, e.g., FAM_000001

Name	Molecule name	Family name

Description	• Molecular formula and weight	• List of member PRD identifiers

	• Specific function (class)	• Literature references

	• Structural details (type)

Chemical details	• List of polymer and nonpolymer entities comprising the molecule	• Synonyms for PRD family members collected from various resources including the PDB and primary citations

	• Polymer or subcomponent sequence• Description of how all components in the molecule are linked	• Reference database IDs and links to various resources that provide information about the family members

	 ○ Intra-entity linkages between components in polymer entities	• Family specific annotations

	 ○ Inter-entity linkages between polymer segments and nonpolymer components (for molecules with grouped representation)	 ○ IDs and information about related small molecule crystal structures in the CSD16

		 ○ Corresponding literature references

Biological details	Name of organism producing the molecule (for naturally produced molecules) and source of this information (e.g. from a database, author or literature)	Annotations about structural, functional and mechanistic details for family members, including pharmacological action (where appropriate)


Time of measurement	Before therapy	After therapy (RCI)	Follow-up (RCI)

Outcome variable

PG-13	42	31 (2.66)	23 (4.59)

CAPS—total	50	27 (3.61)	13 (5.81)

CAPS—Intrusion	17	7 (2.66)	5 (3.19)

CAPS—Avoidance	25	14 (2.27)	6 (3.92)

CAPS—Hyper arousal	10	6 (1.23 NS)	2 (2.47)

BDI	22	15 (2.09)	11 (3.28)


Premises	Area (Wales)	Location and Violence Strata

Urban	Town/Fringe	Rural

North	West	South East	High	Low	High	Low	High	Low

Total (N = 30)	4	2	24	8	6	3	10	1	2

Intervention (N = 16)	2	1	13	5	3	1	6	0	1

Control (N = 14)	2	1	11	3	3	2	4	1	1


Health problem	Overall	Boy	Girl Significance

Myopia	27.1	25.8	28.5***

Caries	69.6	70.0	69.1***

Obesity	9.5	10.6	8.4***

Dysarthria	2.5	3.0	2.0***

Cryptorchidism	-	2.1	-

Heart murmur	1.5	1.6	1.5

Scoliosis	0.4	0.4	0.4

Atopic dermatitis	0.2	0.2	0.2


Dysregulated miRNA (Reference)	Expression status	Proposed target gene

 miR-1 [53] let-7d [55] miR-17 and miR-20a [57] miR-29 [58-59] miR-34 [63] miR-99 family (miR-100 and miR-99a) [64] miR-125b [41] miR-126 [66] miR-133a [67] miR-138 [70-71] miR-153 [72] miR-200 [73] miR-200c [74] miR-222 [75] miR-363 [77] miR-375 [1] 	 Underexpression Underexpression Underexpression Underexpression Overexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression 	 TAGLN2Twist, Snail ITGβ8 LAMC2, ITGA6, TGF-β Unknown IGFIR, mTOR KLF13, CXCL1 and FOXA1 VEGF-A, bFGF MSN GNA12, RhoC and ROCK2 SNAI1 and ZEB2 ZEB1,ZEB2 BMI1/ZEB1 MMP-1 Podoplanin(PDPN) Unknown


Internet Resource	URL

Sequence motif searches

Pfam	http://www.sanger.co.uk/Pfam/

PRINTS	http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/

Prosite	http://www.expasy.org/prosite/

SMART	http://smart.embl-heidelberg.de

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

Structural comparison

CATH	http://www.cathdb.info/latest/index.html

DaliLite	http://www.ebi.ac.uk/DaliLite/

SCOP	http://scop.mrc-lmb.cam.ac.uk/scop/

SSM	http://www.ebi.ac.uk/msd-srv/ssm/

Alignment software

BLAST	http://www.ncbi.nlm.nih.gov/blast/Blast.cgi

ClustalW	http://www.ebi.ac.uk/Tools/clustalw2/

Dcode	http://www.dcode.org

MEGA	http://www.megasoftware.net/

Muscle	http://www.ebi.ac.uk/muscle/

T-coffee	http://www.tcoffee.org/

Alignment optimization

GBlocks	http://molevol.ibmb.csic.es/Gblocks.html

GeneDoc	http://www.nrbsc.org/gfx/genedoc/index.html

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Phylogenetic analysis software

MrBayes	http://mrbayes.csit.fsu.edu/

PhyML	http://atgc.lirmm.fr/phyml/

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Tree-Puzzle	http://www.tree-puzzle.de/

MEGA	http://www.megasoftware.net/

Visualization

Pymol (structural)	http://pymol.sourceforge.net/

NJplot (phylogeny)	http://pbil.univ-lyon1.fr/software/njplot.html

MEGA	http://www.megasoftware.net/

Swiss-Model (structural)	http://swissmodel.expasy.org/

TreeView (phylogeny)	http://taxonomy.zoology.gla.ac.uk/rod/treeview.html

Databases

Ensembl (Sanger project)	http://www.ensembl.org

PDB	http://www.rcsb.org/pdb/home/home.do

NCBI	http://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

UniProt	http://www.expasy.uniprot.org/


Parameter	Pediatric Journals(n = 42)	General Journals(n = 68)

Risk of Bias†

 Adequate Sequence Generation	29 (69)	53 (78)

 Adequate Concealment of Allocation	23 (55)	50 (74)

 Adequate Blinding of Participants and Providers	21 (50)	34 (50)

 Adequate Blinding of Outcome Assessment	25 (60)	53 (78)

 Adequate Handling of Missing Data	30 (72)	53 (78)


 	Stable plaque (SP) 	Unstable plaque (UP) 	P value

 	Median 	25–75% CI	Median 	25–75% CI

Fibrous cap (in μm)	267	181–440	96	0–223	0.02

LCR	0.21	0.08–0.28	0.64	0.54–0.76	<0.001

Neovessels (/0.2 mm2)	0	0–0.3	3	3–5	<0.001


Antipsychotics	MAOIs	Anticonvulsants/Anxiolytics/Others

Chlorpromazine	Hydroxylamine	Benztropine	Phenylephrine

Haloperidol	Selegiline	Phenytoin	Phenobarbital

Sulpiride	Pargyline	Diazepam	Chlordiazepoxide

Flupenthixol	Quinacrine	Nitrazepam


	I.D. 34	I.D. 56	I.D. 81

Tube voltage [kV]	220	220	160

Tube current [μA]	180	180	160

Power [W]	39.6	39.6	25.6

Exposure time [ms]	499	499	999

Filter	Cu 1 mm	Cu 1 mm	none

Number of projections	1200	1200	1200

Voxel size [μm]	28	34	49.5

FOV in horizontal plane [mm]	33	58	82

FOV vertical [mm]	74	104	75

Measurement time [min]	40	60	20*


 	<underline>Outcome: high activity/behavior in children for corresponding activity/behavior category</underline>

Maternal exposure	Baseline	Follow-up

Commuting

 Low activity	1.00	1.00

 High activity	2.72 (1.08, 6.87)‡	3.13 (1.37, 7.16)†

Leisure-time sports

 Low activity	1.00	1.00

 High activity	3.61 (1.14, 11.41)‡	0.87 (0.26, 2.93)

Sedentary

 Low sedentarybehavior	*	1.00

 High sedentarybehavior	*	0.58 (0.35, 0.97)‡


	IFT-A	IFT-B

	IFT122	IFT140	IFT172	IFT52	IFT80	IFT88	TTC-26	TTC30a

Attheya septentrionalis				+

Aulacoseira subarctica	+			+	+	+	+	+

Chaetoceros curvisetus				+		+	+

Corethron hystrix				+

Corethron pennatum				+		+

Coscinodiscus wailesii			+	+	+	+	+	+

Cyclotella meneghiniana				+		+	+	+

Dactyliosolen fragilissimus				+	+

Ditylum brightwellii	+		+	+	+	+	+	+

Extubocellulus spinifer			+	+		+		+

Leptocylindrus aporus				+	+		+

Leptocylindrus danicus	+	+	+	+	+	+	+	+

Leptocylindrus hargravesii	+	+	+	+	+	+	+

Minutocellus polymorphus				+	+	+		+

Odontella aurita	+		+	+	+	+	+	+

Proboscia alata	+	+	+	+	+	+	+	+

Proboscia inermis					+	+	+

Rhizosolenia setigera	+	+	+	+		+

Skeletonema marinoi				+		+		+

Skeletonema menzelii				+				+

Stephanopyxis turris	+		+	+	+	+	+	+

Thalassiosira pseudonanaa				+		+		+

Thalassiosira rotula				+		+		+

Thalassiosira weissflogii	+	+	+	+	+	+	+	+


Cell type	Environment	Number of animals	Peripheral	Intermediate	Central

% EdU + a	% EdU + a	% EdU + a

Number of cells	Number of cells	Number of cells

Vsx2orJ	orJ	4	4% ± 2%	20% ± 3%	31% ± 2%

1,880 cells	2,554 cells	2,490 cells

Vsx2orJ	Mutant chimera	5	26% ± 8%	21% ± 4%	21% ± 5%

			732 cells	798 cells	519 cells

Vsx2wt	Wild type	3	40% ± 5%	47% ± 4%	32% ± 3%

1,390 cells	2,207 cells	2,186 cells

Vsx2wt	Control chimera	4	46% ± 5%	42% ± 5%	28% ± 1%

594 cells	1,093 cells	883 cells

Yfp+	Mutant chimera	3	43% ± 8%	43% ± 8%	32% ± 5%

1,209 cells	2,608 cells	2,169 cells

Yfp+	Control chimera	4	47% ± 2%	44% ± 3%	38% ± 1%

809 cells	1,048 cells	1,378 cells


Description	Example selected for inclusion

Promises (of reduced pain)	If I’m thinner/lose more weight then rejection and criticism won’t hurt so much.

Consolation	I may not be doing so well in some areas of my life but at least I’m thin.

Self-congratulations (on eating behaviour etc.)	I’m doing really well in controlling my eating today.

Threats	If I don’t keep my eating under control, I’m going to get obese and be rejected by everyone.

Cautions regarding eating	That food/eating situation is dangerous. I’m going to have to be really careful about what I eat.

Need to purge	I’m worried that I’ve eaten too much. I need to get rid of it by purging.

Need to exercise	I can’t afford to just sit around, I have to exercise more.

Self-disappointment (at ability to meet dietary ideals)	I’m so disappointed at myself: I’ve failed to live up to my dietary ideals again.

Self-abuse	I am so pathetic and useless. I have no discipline or self-control.

Self-punishment	Because I have failed to live up to my dietary ideals I deserve to be punished by denying myself food or exercising harder.

Self-criticism (lack of self-worth)	I’m such a failure. I try really hard to do well and make friends but I’m just not the type of person I want to be.

Comparisons (with others)	Look at her she’s so thin and she does it so easily. Why can’t I be like her?

Reinterpretations	When they say things like “you’re looking well”, what they’re really meaning is how much weight I’ve put on.

Sensory misperceptions	Just feel that stomach/Look at those thighs (etc.). I feel/look so fat/terrible.

Denial (of symptoms)	Feeling tired and/or cold doesn’t mean there’s anything wrong with me. I just have to be stronger.

Moral judgements	Practising self-restraint is an important virtue. I despise people who have no self-control.

Ruination of life	My concern about food and weight is threatening the other things I want to achieve/get out of life.

Weariness (of constantly thinking about food)	I’m so fed up of constantly thinking about food and what I eat.

Misery (of living with an ED)	Life is so miserable/lonely living like this.

Lost identity	I feel like I don’t really know who I am/what I stand for any more. I’ve lost touch with the real me.

Need for secrecy	People mustn’t find out the way I think or behave concerning food.

Rebellion	I’m fed up of trying to control what I eat. I’m just going to eat whatever and as much as I want!

Pride in ED	When I think about how self-controlled I am around food compared to the average person, I feel quite proud of what I can achieve.

Fear of life without ED	If I let go of my strict control and ideals around eating, I’m really quite frightened about what life would be like.


	Focus groups	Systematic review	Online user-generated content

METHODS

Main approach	Eight focus groups (n = 74)	Searching of databases from the earliest date to October 2014	Analysis of 3,373 reader comments posted online in response to a news article on incentives

	Inclusion criteria: UK adults, aged 18+ years	Databases searched: Medline; Embase; Web of Knowledge; CINAHL; PsycINFO; ASSIA; Sociological Abstracts; Scopus; The Philosopher’s Index; Cochrane Library; SSCI; IBSS	News article topic: feasibility study of financial incentives for breastfeeding

	Method: face-to-face focus groups; audio-recorded; lasting on average 60 min	Inclusion criteria: English language title Published in a peer-reviewed journal Explored acceptability of financial incentives for healthy behaviors Acceptability explored in the public, policy makers, potential recipients, and practitioners	Online news sites searched: BBC; Guardian; Daily Mail; Telegraph; Independent; The Sun

	Analytical approach: thematic analysis using NVivo 10	Analytical approach: thematic analysis using NVivo 10	Inclusion criteria: popular websites defined as those that achieved an average monthly audience of at least five million unique viewers per month across laptop computers, desktop computers, and mobile devices in April and May 2013 Analytical approach: thematic analysis using NVivo 10

RESULTS

Main themes	The nature of fair exchange	Fair exchange	Children are a lifestyle choice

	Design and delivery of incentive schemes	Design and delivery	Financial incentives for breastfeeding are discriminatory and divisive

	Effectiveness and cost-effectiveness	Effectiveness and cost-effectiveness	Creating a culture of entitlement

	Recipients	Recipients	Financial incentives for breastfeeding are potentially insulting

	Impact on individuals and wider society	Impact on individuals and wider society	Psychological impacts on recipients

	“Other” issues		Effectiveness and cost-effectiveness

			Generating initial motivation

			Design and delivery

			Informed choice


Interaction	Odds ratio	Lower 95% CI	Upper 95% CI

Model GP

 age ≥60

low SES to high	1.84	1.54	2.20

middle SES to high	1.57	1.32	1.87

 age<60

low SES to high	0.99	0.89	1.09

middle SES to high	0.96	0.86	1.06

 age ≥60 vs age<60

low SES	4.46	3.93	5.05

middle SES	3.91	3.45	4.44

high SES	2.39	2.04	2.80

Model SD

 age ≥60

low SES to high	1.05	0.83	1.33

middle SES to high	1.08	0.86	1.35

 age<60

low SES to high	0.48	0.41	0.56

middle SES to high	0.78	0.68	0.90

 age ≥60 to age<60

low SES	4.66	3.85	5.65

middle SES	2.93	2.47	3.49

high SES	2.13	1.75	2.60


	All proteins	Human proteins

Total proteins	550,299	20,186

PTM proteins	112,985	13,080

PPI annotation (string)	326,227	17,833

PTM & PPI proteins	65,907	12,541

Drug-binding proteins(DrugBank)	–	1980

PTM & drug-binding proteins	–	1404


	xthr	xtbs	xthr and xtbs

Number of sequences reads obtained	30272	27602	57874

Number of clone sequences obtained	16548	14901	31449

Number of valid sequences	26440	22345	48785

Number of clones with valid sequences	15540	12266	27806

Number of clones with 5' and 3' EST	9354	11486	20840

Number of clones with 5' EST only	4831	0	4831

Number of clones with 3' EST only	1355	780	2135

Average trimmed EST length	522	546	534

Number of contigs	4327	4002	8756

Number of contigs groups	497	289	842

Number of contigs grouped	1210	649	2209

Number of unique contigs	3117	3353	6547

Nulmber of clones in contigs	9616	9268	15642

Number of singletons	7958	4262	17018

Number of clones in singletons	5924	2998	12164

Number of putative transcripts	9538	6640	19553

Max. assembled sequence length	3028	3144	3028

Average assembled sequence length	732	782	745

Max. assembled sequence size	147	144	159

Average assembled sequence size	6	5	5

Number of contigs containing

1	509	97	1152

2	1779	2155	3730

3	452	362	905

4–5	587	545	1159

6–10	505	476	952

11–20	283	207	479

21–30	91	90	174

31–50	80	41	118

50–100	31	26	76

>100	10	3	11


 	N of articles

Exclusively women	15

Pregnant	8

Reproductive age/infertility evaluation	3

Postpartum	2

Others	2

Patients (men and women)	10

Inpatients	4

Primary care	3

Others	3

College students (men and women)	10

General population (men and women, online)	1

Total	36


Against	For

Mutilates healthy organCauses psychological distressInflicts a woundDestroys ability to be fruitfulViolates prohibition against castration	Prolongs life


	Consistent** increased brain activation across ROI’s after treatment (n = 6)	Consistent** decrease (or unchanged) brain activation across ROIs after treatment (n = 7)	Mixed neuroplastic pattern across ROIs after treatment (n = 10)	p value*

AMAT at baseline (s), mean (SD)	1691.6(479)	1070.5(753)	2041.7(349)	0.04

AMAT improvement (s), mean (SD)	693.3(471)	169.8 (203)	430(309)	0.02

Age in years, mean(SD)	58.17(6.8)	57.57 (13.6)	51.7(14.6)	ns

Time since stroke, in years, mean(SD)	2.28(1.5)	1.99 (1.3)	1.34(0.4)	ns


	Patients who underwent a given number of invasive diagnostic procedures (%)

	RIC (N = 195)	Non-RIC (N = 132)

Total number of invasive diagnostic procedures performed

0a	9 (5)	10 (8)

1	99 (51)	68 (51)

2	67 (34)	41 (31)

≥3	20 (10)	13 (9)


Author	Country (ethnicity)	Cases/controls	Diagnosis of cases	Selection of controls

Selvaraj	India (Asian)	210/120	Smear, culture, radiological, clinical response confirmed PTB	Normal healthy spouses and Tuberculosis Research Centre staff, ethnicity and area of residence matched

Fitness	Malawi (African)	181/533	Smear, culture, histology confirmed TB, HIV negative	No history or symptom of TB; not first or second degree relatives of the cases; age, sex and area of residence matched

Vejbaesya	Thailand (Asian)	149/147	Smear, culture, clinical and radiological response confirmed PTB, HIV negative	Unrelated healthy blood bank donors

Ates	Turkey (Caucasian)	128/80	Smear, culture, pathological, radiological , clinical response confirmed PTB,EPTB	No history of TB noted on chest radiography, age and sex matched

Trajkov	Republic of Macedonia (Caucasian)	75/301	Smear/culture confirmed PTB	No family history of TB, nationality and area of residence matched

Merza	Iran (Asian)	117/60	Smear and radiological confirmed PTB	Nurses, doctors and TB staff with no laboratory or clinical sign of diseases development, age, sex and nationality matched

Sharma	India (Asian)	185/155	Smear, culture, histology, radiological , clinical response confirmed PTB,EPTB,HIV negative without chronic illness	Without a family history of TB or any other related disease and a possibility of a latent tuberculosis infection, socioeconomic status and ethnicity matched

Anoosheh	Iran (Asian)	93/103	Smear and culture confirmed PTB	No history of TB

Lin	China (Asian)	46/40	Pathological examination and clinical response confirmed EPTB	NR


Socio–demographic characteristic	N	Per cent (95 % CI)

Age group –

 11–15 years	53	3.3 (2.4–4.2)

 16–17 years	74	5.5 (4.3–6.7)

Highest level of parent/carer education –

 Bachelor degree or higher	54	4.7 (3.4–6.0)

 Diploma or cert III/IV	44	3.0 (2.1–4.0)

 Year 11 or 12	13	3.4 (1.5–5.3)

 Year 10 or below	16	5.7 (2.7–8.6)

Parent/carer labour force status –

 Both carers employed	59	3.4 (2.5–4.3)

 One carer employed, one carer not in employment	29	4.8 (2.8–6.8)

 Both carers not in employment	7	8.7 (2.3–15.0)

 Sole carer employed	24	3.9 (2.3–5.5)

 Sole carer not in employment	8	3.5 (0.9–6.1)

 Not stated	0	–

Housing tenure –

 Owned outright	12	2.5 (1.0–4.1)

 Owned with a mortgage	65	3.5 (2.6–4.4)

 Rented – public housing	9	6.5 (2.4–10.6)

 Rented – other	41	5.3 (3.5–7.1)

 Other	0	–

Annual household income –

 Less than $52,000	32	4.4 (2.8–6.0)

 $52,000–129,000	54	3.6 (2.6–4.6)

 $130,000 or more	37	4.3 (2.9–5.8)

Child’s country of birth –

 Australia	107	3.7 (3.0–4.5)

 Overseas	20	5.0 (2.6–7.4)

Family type –

 Intact family	73	3.8 (2.9–4.7)

 Step family	7	3.7 (0.7–6.7)

 Blended familya	11	4.4 (1.6–7.1)

 Lone parent family	33	3.9 (2.5–5.3)

 Other family	3	8.8 (0.00–18.8)

Geographic level of remoteness –

 Major cities	97	4.6 (3.6–5.5)

 Inner regional Australia	22	2.8 (1.6–4.0)

 Outer regional Australia	6	2.6 (0.2–5.0)

 Remote Australia	2	3.7 (0.0–8.8)


Feature	Description	Information gain

Feature 1	Number of neighbours in which the label is assigned	0.16

Feature 2	Sum of similarity scores between the document and all the neighbours’ document where the label appears	0.17

Feature 3	Check whether all constituted tokens of the label appear in the target document	0.01

Feature 4	Check whether one of the label entries appears in the target document	0.03

Feature 5	Frequency of the label if it is contained in the document	0.03

Feature 6	Check if the label is contained in the document title	0.02


			Larval temperature (°C)

	Adult temperature (°C)		27 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 27 °C)

1st blood meal		Log odds of laying eggs	−0.783b	−1.658	−0.876

23 ± 1	log-likelihood ratio test	−1.187	−2.455	−1.515

p-value	0.235	0.014	0.130

27 ± 1	Log odds of laying eggs	−2.565	−4.069	−1.504

log-likelihood ratio test	−2.383	−3.828	−3.086

p-value	0.017	<0.001	0.002

31 ± 1	Log odds of laying eggs	0.767c	−0.028	−0.795

	log-likelihood ratio test	1.386	−0.048	−1.392

	p-value	0.166	0.962	0.164

2nd blood meal		Log odds of laying eggs	−1.952	−3.312	−1.36

23 ± 1	log-likelihood ratio test	−2.398	−3.805	−2.276

p-value	0.016	<0.001	0.023

27 ± 1	Log odds of laying eggs	−1.161	−2.496	−1.335

log-likelihood ratio test	−1.613	−3.486	−2.534

p-value	0.107	<0.001	0.011

31 ± 1	Log odds of laying eggs	1.121	0.359	−0.762

log-likelihood ratio test	1.557	0.465	−1.218

p-value	0.120	0.642	0.223


Sample	Layer thickness [nm] mean ± standard deviation

NCO-sP(EO-stat-PO) sample1	19.6 ± 0.4

NCO-sP(EO-stat-PO) sample2	24.4 ± 1.0

NCO-sP(EO-stat-PO) sample3	12.0 ± 0.8


Doped Atoms X	Concentration (%)	Band Gap (eV)	CBM	VBM

-	0.00	1.59	Γ	Γ

S	1.56	1.52	Γ	Γ

S	2.78	1.48	Γ	Γ

S	6.25	1.43	Γ	Γ

O	6.25	1.54	Y	Γ

Te	6.25	1.39	Γ	Γ


Clinical Characteristics	Mean (±SD) or Frequency(%)

Mean Age in years	34.1±13.01

Sex

 Males	126 (60.3%)

 Females	83 (39.7%)

Location of pain

 Flank Pain	156 (75.4%)

 Costovertebral angle pain	53 (24.6%)

Radiation

 None	85 (48.8%)

 Front	64 (30.6%)

 Groin	50 (23.9%)

 Genitalia	10 (4.7%)

Onset of pain

 Sudden	100 (47.8%)

 Gradual	109 (52.2%)

Severity of pain

 Mild to Moderate	133 (63.6%)

 Severe	76 (36.4%)

Pain Character

 Colicky	122 (58.4%)

 Continuous	87 (41.6%)

Urinary symptoms

 None	56 (26.8%)

 Dysuria	99 (47.4%)

 Frequency/urgency	39 (18.7%)

 Hematuria	15 (7.2%)

Systemic symptoms

 None	90 (43.1%)

 Nausea, vomiting	109 (52.2%)

 Fever	10 (4.7%)

Aggravating factors

 None	111 (53.1%)

 Movement	67 (32.1%)

 Rest	31 (14.8%)

Past history of renalstones

 Yes	60 (28.8%)

 No	149 (71.2%)

Findings on examination

 None	152 (72.7%)

 Costovertebral angle tenderness	57 (27.3%)


 	Tested in past 12 m	Not tested in past 12 m	P*

Overall number of subjects (N = 349**)	260	89

Facilitators by code**

Health concerns for self or others	65 (15.4)	12 (12.5)	0.47

 Perceived risk	15 (3.6)	3 (3.1)	0.83

 Lab characteristic	15 (3.6)	3 (3.1)	0.83

 Access to transportation	36 (8.6)	11 (11.5)	0.37

 Mobile testing center/SEP	75 (17.8)	13 (13.5)	0.31

 Adequate time	9 (2.1)	4 (4.2)	0.25

 Knowledge of testing	25 (6.7)	9 (9.4)	0.22

 Free testing	85 (20.2)	13 (13.5)	0.13

 Access to MD/PCP	28 (6.7)	5 (5.2)	0.60

 Not having to take initiative	5 (1.2)	0 (0)	0.28

 Rapport with provider	10 (2.4)	2 (2.1)	0.86

 Confidentiality	8 (1.9)	1 (1.0)	0.56

 Motivation	5 (1.2)	1 (1.0)	0.90

 Other	16 (3.8)	8 (8.3)	0.06

 Nothing	24 (5.7)	11 (11.5)	0.04


Identification	Description of the gene	Primers	Primer efficiency

A-E4	Mitogen-activated protein kinase	F: 5′- GAAGATGAGAAACCACAAGCG	90 %

R: 5′- CATTCTGAGGAACTTGGAGAGG

C-G1	Importin subunit alpha1a	F: 5′- GAACTCATTTTGTGCCCCATC	92 %

R: 5′- GCTGAGGGATTGGAAAAGATTG

E188	Intracellular Ras-group-related LRR protein 9	F: 5′- GAGAGGCAGGATTGGAGATTG	94 %

R: 5′- TCCGCATCCTTCAACATCTTC

E-E3	Polyadenylate-binding protein RBP47	F: 5′- TCCTAATGAGCCTAACAAACCTG	92 %

R: 5′- TCCGTCTTATTGCCTTCCAC

VHA-A1	V-ATPase catalytic subunit A1	F: 5’- CGAGAAGGAAAGCGAGTATGG	107 %

R: 5’- TCATTCACCATCAGACCAGC

B-D5	Vacuolar H + -ATPase V0 sector	F: 5′- GCAGTCATTATCAGTACCGGG	89 %

R: 5′-TCTAACACCAGCATCACCAAC

B-E2	Pectin acetylesterase	F: 5’-CACACCCACAAAGAGAAACAG	103 %

R: 5’-TTCCAAGAATGCCCCTTCAG

12.	XTH	F: 5’-AGAGGTGGGCTTGAGAAAAC	93 %

R: 5’-GAACCCAACGAAGTCTCCTATAC

B-D9	26S proteasome	F: 5’-TCTTGTCCTCTTTCTGTTCCTTATC	95 %

R: 5’-AATCCTTGCCTCACTTCCAG

C-A3	Histone H2B	F: 5′- TTGGTAACAGCCTTAGTTCCTC	89 %

R: 5′- AAAGCCTACCATCACTTCTCG

PP2ACS	PROTEIN PHOSPHATASE 2A catalytic subunit	F: 5’- CGATGTGTGATCTCCTATGGTC	98 %

R: 5’- AAGCTGATGGGCTCTAGAAATC


Time (d)	Number of identified proteinsa	Number of secreted proteinsb (percentage of identified proteins)

0	89	31 (35 %)

7	1009	150 (15 %)

14	1077	163 (15 %)

21	1149	170 (15 %)

28	1151	170 (15 %)

42	1035	157 (15 %)


	N (%)

Surgical resection

 Yes/no	13 (25)/40 (75)

 Margin: R0/R1	10 (19)/3 (6)

Type of surgery

 Liver resection	3 (6)

 CRS and HIPEC	5 (9)

 Primary tumor resection and liver resection	3 (6)

 Primary + CRS and HIPEC1	1 (28)

 Lung resection	1 (2)


Authors	Population	Outcome parameters	Validity	Quality	Quantity	Activity

Dobkin et al. [33]	Stroke	Walking speed, bouts of walking, gait symmetry	Leave-one-subject-out method	-	x	Walking

Zampieri et al. [44]	PD	Stride length, stride velocity, cadence, peak arm swing velocity on the MAS, and turning velocity	Leave-one-subject-out method	-	x	Sitting, standing, walking, turning

Mizuike et al. [37]	Stroke	Accelerometers derivatives, raw RMS, normalized RMS, autocorrelation function	Cross-validation	x	x	Walking

Prajapati et al. [40]	Stroke	Walking bouts, total walking time, gait speed, number of steps, gait symmetry, swing symmetry, cadence	Cross-validation	x	-	Walking


Statement	N	Mean [Range]

Feel supported in carrying out my work at the clinic	20	4.05 [2-5]

Feel confident when carrying out my work at the clinic	20	4.65 [4-5]

Feel the work I do is important and well valued	20	4.55 [2-5]

Find the work load at the clinic is too demanding	20	3.3 [2-5]

The facilities at the KCC clinic are adequate for me to carry out my work	20	2.65 [1-5]

Work at KCC is stressful	20	2.3 [1-5]

Training that I have undertaken has improved my skills	20	4.7 [4-5]

Training has improved the knowledge	20	4.4 [4-5]

Quality of care I provide has improved	20	4.6 [4-5]

Each patient is given the right amount of time	20	3.45 [2-5]


Disease	Gene	Inheritance mode	Other clinical features (main)

Monogenic diseases causing small artery occlusion (lacunar) ischemic stroke

 CADASIL [78]	NOTCH3	autosomal dominant	migraine with aura, mood disturbance, progressive cognitive impairment

 CARASIL [79, 80]	HTRA1	autosomal recessive	alopecia, dementia, gait disturbance, low back pain, mood disturbance

 RVCL [81–84]	TREX1	autosomal dominant	visual loss, stroke, dementia, seizures, headache, personality disorders

Monogenic diseases causing large artery and small artery occlusion (lacunar) ischemic stroke

 Sickle cell disease [85, 86]	HBB	autosomal recessive	more seldom hemorrhagic stroke, vaso-occlusive or painful crisis, retinopathy, chronic leg ulcers, increased susceptibility to infection, anemia

 Homocystinuria [87, 88]	CBS*	autosomal recessive*	thromboembolism, mental retardation, ectopia lentis, skeletal abnormalities

 Fabry disease [89–91]	GLA	X-linked	acroparesthesia, hypohidrosis, angiokeratoma, chronic kidney disease, cardiomyopathy

 PXE [92–94]	ABCC6	autosomal recessive	peau d’orange lesions, ocular complications, hypertension, peripheral artery disease, coronary artery disease, gastrointestinal bleeding

Monogenic diseases causing ischemic stroke of other etiologies

 Vascular EDS [95–98]	COL3A1	autosomal dominant	dissection and rupture of arteries, rupture or hollow organs, easy bruising, thin skin with visible veins

 Marfan syndrome [99–102]	FBN1*	autosomal dominant	aortic root dilatation and dissection, ectopia lentis, marfanoid habitus, dural ectasia, pneumothorax

Monogenic mitochondrial disorders

 MELAS [103–105]	tRNA Leu	maternal inheritance	seizures, recurrent headaches, anorexia, recurrent vomiting, myopathy with exercise intolerance

Monogenic diseases causing intracerebral hemorrhage

 CAA [106–110]	APP, CST3	autosomal dominant	dementia, transient neurological symptoms and seizures

 COL4A1 syndrome [111–115]	COL4A1	autosomal dominant	more seldom lacunar ischemic stroke, porencephaly, intracranial aneurysms, retinal arteriolar tortuosities and haemorrhage, cataract, Axenfeld-Rieger syndrome, hematuria, renal cysts, mild renal failure, muscle cramps


Mangifera indica L.Nutrition value per 100 g

Energy	60 Kcal

Fruit composition	Quantity

Carbohydrates	14.98 g

Protein	0.82 g

Fat	0.38 g

Fiber	1.6 g

Vitamins

Vitamin C	36.4 mg

Vitamin E	1.12 mg

Vitamin A	1082 IU

Niacin (vit B3)	669 μg

Pantothenic acid (vit B5)	160 μg

Pyridoxine (vit B6)	119 μg

Riboflavin (vit B2)	38 μg

Thiamin (vit B1)	28 μg

Folates	43 μg

Vitamin K	4.2 μg

Minerals

Potassium	168 mg

Phosphorus	14 mg

Calcium	11 mg

Magnesium	10 mg

Sodium	1 mg

Copper	110 μg

Iron	160 μg

Manganese	27 μg

Zinc	90 μg

Carotenoids

β−Carotene	445 μg

α−Carotene	17 μg


Cultivar (cv.)	Number of samples	Geographical origin

Coratina	10	Bari (Apulia, Italy)

Ogliarola Garganica	10	Gargano, Foggia (Apulia, Italy)

Ogliarola Barese	10	Bari (Apulia, Italy)

Cima di Mola	10	Bari (Apulia, Italy)

Picholine	10	Bari (Apulia, Italy)

Peranzana	3	San Severo, Foggia (Apulia, Italy)

Carolea	8	Calabria

Rossanese	3	Calabria

Picual	3	Spain

Kalamata	3	Greece

Koroneiki	3	Greece


Workflow A	Workflow B	Workflow C

+ ease of application	+ very straightforward, no parameters or thresholds	+ can integrate many existing programs

+ software is available	+ guaranteed result in several rounds	+ different algorithms address particular properties of promoters

+ the spectrum of existing methods covers all particular aspects of transcriptional regulation	 	+ optimization of a collection of combinatorial modules instead of optimization of each module separately

– big number of methods to choose from (over 150 can be found in the Internet)	– may lead to a scission of a functional module rendering all parts non functional	– huge number of predicted features require much memory and CPU = > specificity filtering should be applied before modules optimization

– relative performance of methods differs for different datasets	– high lab work and time investments

– chance of a correct prediction is ~5-10% [5]

– impossible to estimate the number of required rounds


First author	Year	Ethnicity	Disease	Sample	Number	Gender (M/F)	Age (years)	Method	NOS score

Tumor	Benign	Normal

Longo [29]	2014	Caucasians	HNSCC	Tissue	96	0	79	75/21	59 (20~90)	qMSP	8

Liu [28]	2013	Asians	CC	Tissue	40	0	40	0/40	—	MSP	6

Weiss [10]	2011	Caucasians	HNSCC	Tissue	49	0	31	—	63.7 ± 11.8	MSP	7

Yang [9]	2010	Caucasians	CC	Tissue	60	40	20	—	46 (38~57) 	qMSP	7

Yanatatsaneejit [20]	2008	Asians	NPC	Tissue	46	0	20	—	—	Duplex MSP	6

Brait [5]	2008	Caucasians	BCa	Tissue	93	0	26	—	67 (39~83)	qMSP	8

25	0	5	—	66 (34~84)	qMSP

Yu [21]	2003	Asians	BCa	Tissue	132	23	0	107/25	—	MSP	8

Kitkumthorn [19]	2006	Asians	CC	Tissue	30	24	25	—	—	Duplex MSP	6

Tokumaru [12]	2004	Asians	HNSCC	Tissue	20	0	11	—	—	MSP	6

Yu [21]	2003	Asians	HCC	Tissue	28	0	28	—	—	MSP	6


	Migraine in AH-group	Migraine in Non-AH group	Total

Females	6 (50 %)	48 (33 %)	54 (34 %)

Males	1 (11 %)	7 (8 %)	8 (8 %)

Total	7 (33 %)	55 (24 %)	62 (24 %)


 	T. muris L1 assay	Adult T. muris assay

Duration of drug assaya	24 hours	72 hours

Number of parasites per well	20 to 200	2 to 4

Dissection of animal host required	No	Yes

Subjective analysis	Yes	Yes

Viability marker alternative	No	Yesb

Total operational hours	3.5 hoursc	6.5 hoursd

Applicability to high-throughput screening	No	No


	Sense	Antisense

Reference gene

 Gapdh	5′-ggcaaattcaacggcaca-3′	5′-gttagtggggtctcgctcctg-3′

Inflammation marker

 S100A8	5′-tgtcctcagtttgtgcagaatataaat-3′	5′-tttatcaccatcgcaaggaactc-3′

 S100A9	5′-ggcaaaggctgtgggaagt-3′	5′-ccattgagtaagccattcccttta-3′

Mobilization markers

 CCL2	5′-ttggctcagccagatgca-3′	5′-cctactcattgggatcatcttgct-3′

 CX3CL1	5′-gtgccattgtcctggagac-3′	5′-catttctccttcgggtcag-3′

 KC	5′-tggctgggattcacctcaa-3′	5′-gagtgtggctatgacttcggttt-3′

 MIP-1α	5′-caagtcttctcagcgccatatg-3′	5′-tcttccggctgtaggagaagc-3′

Cell markers

 CX3CR1	5′-gagtatgacgattctgctgagg-3′	5′-cagaccgaacgtgaagacgag-3′

 CCR2	5′-ctatctgctcaacttggccatct-3′	5′-tgagcccagaatggtaatgtga-3′

 Ly6C	5′-gcagtgctacgagtgctatgg-3′	5′-actgacgggtctttagtttcctt-3′

 F4/80	5′-aatcctgtgaagatgtgg-3′	5′-gagtgttgatgcaaatgaag-3′

Adhesion molecules

 LFA1	5′-gaatgtatgaagggcaaagtc-3′	5′-gcagcaaactggtaggaag-3′

 VCAM	5′-ccaagtctctccaaaagatatacagctt-3′	5′-atgacggtgtctccctct-3′

 L-selectin	5′-actgctctgttgtgacttcc-3′	5′-tgtatggcgactaaatctgtg-3′

 PECAM1	5′-tccctgggaggtcgtccat-3′	5′-gaacaaggcagcggggttta-3′

 VE-cadherin	5′-tcctcttgcatcctcactatcaca-3′	5′-gtaagtgaccaactgctcgtgaat-3′


locus	primer	source	sequence

COI	LCO_Hym (C1-J-1514)	[75]	5'-TATCAACCAATCATAAAGATATTGG-3'

	C1-J-1580	new	5'-ACATCTTTAAGAATAATTATTCG-3'

	Nancy-short (C1-N-2194)	[76]	5'-CCCGGTAAAATTAAAATATAAAC-3'

	Pat (TL2-N-3014)	[76]	5'-TCCAATGCACTAATCTGCCATATTA-3'

28S	28S for (D2-3665F)	[82]	5'-AAGAGAGAGTTCAAGAGTACGTG-3'

	28Srev (D3-4283R)	[82]	5'-TAGTTCACCATCTTTCGGGTCCC-3'

TPI	L1F	[83]	5'-CTKCGTBGGNGGNAACTGGAAGATGA-3'

	L1R	[83]	5'-CCRATRGCCCANACNGGYTCRTA-3'


Range(mA)	Heaterresistance (Ω)	Thermocoupleresistance (Ω)	Output emf(mV)	Reversalerror (μA/A)	Timeconstant (s)

5	50 to 60	8 to 13	11	50	<2

10	30 to 40	7 to 8	9	220	<2

20	20 to 25	3 to 5	9	250	<2

30	6 to 7	3 to 5	9	240	<2

50	3 to 4	3 to 5	9	100	<2

100	1 to 2	3 to 5	10	140	<2

250	0.5 to 1.0	2 to 4	11	130	<3


 	0 additional risk	1 additional risk	2 additional risk	3 additional risk	4 additional risk

Physical Activity Risk

No	88	223	211	114	30

Yes	168	591	815	481	157


Code	Value	%agea	Description

J	140	7.28	Translation

A	0	0	RNA processing and modification

K	101	5.25	Transcription

L	128	6.66	Replication, recombination and repair

B	1	0.05	Chromatin structure and dynamics

D	24	1.25	Cell cycle control, mitosis and meiosis

Y	0	0	Nuclear structure

V	47	2.45	Defense mechanisms

T	62	3.23	Signal transduction mechanisms

M	66	3.43	Cell wall/membrane biogenesis

N	5	0.26	Cell motility

Z	0	0	Cytoskeleton

W	0	0	Extracellular structures

U	26	1.35	Intracellular trafficking and secretion

O	56	2.91	Posttranslational modification, protein turnover, chaperones

C	79	4.11	Energy production and conversion

G	40	2.08	Carbohydrate transport and metabolism

E	137	7.13	Amino acid transport and metabolism

F	61	3.17	Nucleotide transport and metabolism

H	58	3.02	Coenzyme transport and metabolism

I	41	2.13	Lipid transport and metabolism

P	77	4.01	Inorganic ion transport and metabolism

Q	15	0.78	Secondary metabolites biosynthesis, transport and catabolism

R	179	9.31	General function prediction only

S	133	6.92	Function unknown

-	554	28.82	Not in COGs


Response	N	%

Nothing would happen	34	30.1

My Doctor (the researcher) would not be happy with me	10	8.8

I don't know	8	7.1

Could be a bad decision for me clinically	38	33.6

Others	23	20.4

"I might regret not utilizing the opportunity for the free treatment"

"How can I stop participation when I have come to seek medical help?"

"I would discourage others who want to join"

"I would spoil their work."

"It is compulsory"

"It shows that there is no reason for my coming"

"It is a research work, I can't stop"

"I would be insulting the Doctors by stopping"

"I would have cheated myself"

"It shows that I'm not serious"

"I can't stop because Doctor is doing something good"

"I would go back with the problem I came with"

"Doctor would go away"

"I can't say I would stop participation since I chose to come for my health sake"

"My conscience would not allow me because it is helpful"

"I want to know what they are doing" etc


Group	Surgery time* (mean ± SD)	Extubation time* (mean ± SD)

TRA	95.3 ± 17.4	6.6 ± 2.4

MET 0.5	98.2 ± 15.2	7.2 ± 1.6

MET 0.7	98.5 ± 12.8	7.3 ± 2.2


		Median ± SD of PRB expression (2^-∆Ct)

PRB status at day 1	Day 1	Day 15

Control group	PRB+	0.014 ± 0.01	0.010 ± 0.02

PRB-	0.007 ± 0.00	0.007 ± 0.001

Treated group	PRB+	0.014 ± 0.01	0.011 ± 0.01

PRB-	0.006 ± 0.002	0.006 ± 0.003


Drug	Brain disease	Mechanism	Reference

ω-3 PUFA	ADHD	Nonspecific antioxidant effect	[151, 152]

Vitamin C	Vascular dementia	Free radical scavenger	[153]

Hyperbaric O2	Autism	Anti-inflammatory and reduces oxidative stress	[157]

H2S	Focal cerebral ischemia/reperfusion	Inhibits oxidative phosphorylation, inflammation, and apoptosis	[159]

H2-rich saline	Focal or global cerebral ischemia/reperfusion	Reduces oxidative stress and inflammation	[160, 161]

Lithium	Healthy volunteers	Prevents/or reverses DNA damage, lipid peroxidation, and free radical formation	[164]

Pifithrin-μ	Perinatal hypoxic-ischemic brain damage	Inhibition of the apoptotic pathways and reduction of the oxidative stress	[166]

Telmisartan	Vascular dementia	Anti-inflammatory and antioxidant effects	[174–176]

Nanodrugs	 	ROS scavengers	[177]

Triterpenoids	Parkinson	Antioxidants via Nrf2/ARE pathway	[146]

PPARgamma agonists	Neurodegenerative diseases	Anti-inflammatory	[162–164]


Main Reason for Being Here	Frequency	Percent

Fracture	6	12.8

Strain, sprain, dislocation	7	14.9

Cut, bite, penetrating injury, open wound	19	40.4

Bruise, scrape, superficial wound	9	19.1

Concussion, closed head injury	2	4.3

Organ system injury/multiple organ injury	2	4.3

Other	1	2.1

Unknown	1	2.1

Total	47	100.0


Predictors	Regression coefficient	Odds ratio	95% CI	Risk score = Regression coefficient × 25

Pre-existing diseases (CCI >3)	2.02	7.52	2.01 to 28.1	50.5

Parent to children <18 years	1.26	3.51	1.39 to 8.89	31.5

Previous psychological problems	1.14	3.13	1.12 to 8.76	28.5

In-ICU agitation	0.8	2.23	-0.80 to 6.22	20

Unemployed/sick-leave at ICU admission	0.48	1.62	-0.54 to 4.88	12

Appeared depressed in ICU	0.30	1.35	-0.55 to 3.31	7.5


Measure	Outcome results

Maternal

 Dams’ daily mean fluid consumption (mL/day)

For 14 days before mating	14.7 ± 0.8

During gestation	29.5 ± 1.8

PND1–PND10	46.8 ± 3.7

 Dams’ weight (g)

14 days before mating	223 ± 6

At mating	247 ± 7

Total weight gain during pregnancy	127 ± 6

 Mating success rate (%)	93.8 ± 1.2

Litter and physical milestones

 Length of gestation (days)	20.5 ± 0.2

 Mean litter size (pups)	11.9 ± 0.4

 Sex distribution at birth [male/female (%)]	54/46

 Litter mortality (dead newborn pups/litter)	0.2 ± 0.1

 Pup mortality during lactation (%)	1.9 ± 0.1

 Eye opening [male/female (%)]

At PND14, one or both eyes	78 ± 5/75 ± 6

At PND16, both eyes	100/100

Female offspring body weight (g)

 At birth (PND0)	6.12 ± 0.14

 PND10	20.3 ± 1.2

 PND21	50.1 ± 2.1

 PND90	254.6 ± 4.8


Group	First dose (μg/kg) 30–60 min before surgery	Second dose (μg/kg) 24 h after surgery	Total dose (μg/kg)

1	0.25	0.25	0.5

2	0.5	0.5	1.0

3	0.75	0.5	1.25

4	1.0	0.5	1.5

5	1.0	1.0	2.0


Scaffold Designation	Composition

Chitosan (Ch) 1%	Gelatin (Gel) 1%	nHAp 0.25%	nCuZn Alloy 0.01%

Final Concentrations in Blend (%)

Ch/Gel	0.5	0.25	-	-

Ch/Gel/nHAp	0.5	0.25	0.0625	-

Ch/Gel/nHAp/nCuZn	0.5	0.25	0.0625	0.00025


	Absence of protective haplotypes	At least one protective haplotypes

Anti-MAP2694 Abs	Negative	258 (71 %)	103 (29 %)

Positive	122 (80 %)	31 (20 %)


Household characteristics	Value

% of houses with

 Land ownership	42.2

 Head of household with agriculture related occupation	18.1

 Ground water as main source of drinking water	61.8

 Piped water in own house	26.2

 Access to water seal latrine	74.7

 Wood/cow dung as main Fuel used for cooking	69.1

 Tobacco smoker in the HH	60.5

Mean (Standard Deviation) number of

 Persons per household	5.97 (2.61)

 Children ≤ 10 years per household	1.75 (1.54)

 Sleeping rooms per household	1.89 (0.98)


No.	Age/sex	Etiology	Defect location	Flap dimensions (cm)	Complications

1	45/f	Trauma	Heel avulsion 	24×11	Partial graft loss at lower donor site

2	45/m	Verrucous carcinoma of heel	Heel	23×10	None

3	42/m	Trauma	Avulsion of heel and sole of midfoot	28×14	Patchy graft loss, healed within 20 days with dressings.

4	38/f	Squamous cell carcinoma of heel	Heel region	26×12	None

5	42/m	Verrucous carcinoma 	Heel region	23×10	None

6	60/m	Squamous cell carcinoma of heel	Heel region extending in to the sole	26×11	Partial graft loss at lower donor site

7	43/f	Trauma	Medial malleolus with dorsal foot region	25×10	None

8	48/m	Verrucous carcinoma	Heel region	22×10	Exposed fibula – 5 cm fibula excised and covered with left flap during final inset

9	49/f	Trauma	Medial malleolus region	21×10	None

10	38/m	Trauma	Heel with tendoachillis region	24×11	Partial graft loss at lower donor site


(1) Events were classified as related to knowledge-acquisition goals if their content fulfilled any of the following criteria and did not conflict

with the criteria for emotional goals.

(a) Knowledge-acquisition goals related to the future (if an event referred to words related to time, such as 6 months later, or in the future; the event was classified as related to knowledge-acquisition goals. There was also a wide range of non-future events which were coded as present-focused events).	e.g., “The problems in middle school math competitions became increasingly difficult in today’s classes, which stumped a number of my classmates. Only three questions were covered in the two classes, and I did still not understand the problem-solving process. I was very concerned about my future studies.”

(b) Knowledge acquisition	e.g., “This morning, I attended a project in which student volunteers taught us how to use computers face-to-face at the University of Posts and Telecommunications. The two problems that I didn’t understand before were solved. Thus, I was very happy.”

(c) An individual’s observation, understanding; learning of social survival skills through interaction with others; and inspiration for knowledge acquisition from the people around them, events, and their own life experiences.	e.g., “Today, I went to the Aging Lab at Beijing Normal University to take part in tests. It was a very happy thing and I acquired much knowledge constantly. It’s never too late to learn.”

(d) Realization of one’s own shortcomings through interaction with others and engagement in periodic self-assessment.	e.g., “The lesson on the Study on New Venture’s Creation was boring. The teacher suddenly asked, ‘What are you interested in? What do you care about?’ Then, I realized that I did not know how to answer these questions. I have spent days and months without doing anything meaningful. While listening to classmates’ answers, I was lost in thought.”

(e) Use of activities and events to provide information (reading books, etc.)	e.g., “On Friday evening, I turned on the computer and watched Tian tian Xiang shang, a famous, entertaining talk-show in China. The hosts sounded very happy. I should imitate their speech to improve my public-speaking skills.”

(2) Events were classified as related to emotional goals if their content fulfilled any of the following criteria and did not conflict

with the criteria for knowledge-acquisition goals.

(a) Emotional goals related to the present (if the event referred to words related to time, such as now, the present, and were within 6 months; the event was classified as related to emotional goals).	e.g., “On Sunday, my husband’s colleague, whom we had not seen for many years, was coming. We were all happy. They were very excited when they chatted about their time at the company.”

(b) Mood control rather than pursuit of new knowledge (emotion can be affected by tourism, scenery, environment, weather, prices, or physical conditions, and individuals can acquire emotional experience and become inspired by events and the people around them).	e.g., “This morning, when I pulled back the curtain, a silver world appeared outside the window! Snow was everywhere, just lying on the trees. An unseasonable snowfall gave a surprise to spring. Particularly in these days of the hazy weather, the snow scene was a rare and beautiful thing.”

(c) Preference for spending time with family and close friends, rather than going to a party to obtain emotional satisfaction (sometimes, individuals need to feel needed and supported by others, and people acquire positive emotional experience by helping others).	e.g., “On the way to the library, a man asked me how to get to the classroom. I explained the way to him clearly and patiently. I had a strong feeling of presence and being needed as soon as he thanked me, which made me very happy.”

(d) A focus on the meaning of life and emotional intimacy (individual’s might seek to control their own moods or to engender a positive emotional experience).	e.g., “Although it was late, I still went for a walk with my friend. After I poured out my problems to her, I felt quite relaxed. She calmed me down and let me think about some things objectively. I thanked her a lot.”

(e) A focus on emotional rewards achieved through various activities or participation in social activities for the sake of an emotional experience.	e.g., “I had a good time with my friends at the beginning of this morning’s exercise. The teacher who taught us to make fans came to the classroom at 9:00. Some of her behaviors made us feel uncomfortable. I attended this class for pleasure, but I was unhappy. So I left the classroom and looked for pleasure elsewhere.”

(3) If an event could be classified as related to either an emotional or a knowledge-acquisition goal; it was classified as a mixed event.	e.g., “Today, in art class, the teacher taught us how to draw a peony. It was good to understand new things; it put us in a good mood and we gained something.”

(4) Descriptions of some events were too simple and did not contain distinguishing information. These events were considered non-specific.

Examples of these events include “Let the robot clean the house” or “Cooking meat for dinner.”


Trait	Total cases	Pathologically confirmed cases

DLB	788	667

AD	959	113

PD	804	0


Pathway name	No. of genes	p-Value

Antigen processing and presentation	9	0

Chemokine signaling pathway	13	0

Complement and coagulation cascades	7	0

Cytokine-cytokine receptor interaction	23	0

Natural killer cell mediated cytotoxicity	9	0

Classical Complement Pathway	3	1.00E-04

Complement Pathway	3	4.00E-04

Alternative Complement Pathway	2	0.0021

Granzyme A mediated Apoptosis Pathway	2	0.0036

Toll-like receptor signaling pathway	4	0.0071

Intestinal immune network for IgA production	3	0.009

CCR3 signaling in Eosinophils	2	0.0111

Caspase Cascade in Apoptosis	2	0.0121

NOD-like receptor signaling pathway	3	0.0121

MAPK signaling pathway	6	0.0168

ECM-receptor interaction	3	0.0232

Jak-STAT signaling pathway	4	0.0284

IFN gamma signaling pathway	1	0.0478

B Lymphocyte Cell Surface Molecules	1	0.0611

T cell receptor signaling pathway	3	0.069


	n	%	Median	Range	Interquartile range

Wait time for first visit (time 1)			6	1–24	3–9

 1 month	3	5.3%

 2 months	7	12.3%

 3 months	10	17.5%

 4 months	4	7.0%

 5 months	1	1.8%

 6 months	10	17.5%

 7 months	2	3.5%

 8–9 months	5	8.8%

 10–12 months	7	12.3%

 13–18 months	5	8.8%

 19–24 months	3	5.3%

Wait time from first visit to diagnosis (time 2)			1	0–6.5	0.5–2

 0 months	7	12.3%

 0.25 months	3	5.3%

 0.5 months	5	8.8%

 0.75 months	5	8.8%

 1 month	18	31.6%

 1.5 months	2	3.5%

 2 months	7	12.3%

 3 months	4	7.0%

 4.5 months	2	3.5%

≥ 6 months	4	7.0%

Total wait from referral to diagnosis			7	2–26	4–12

< 2 months	3	5.3%

 2–3 months	6	10.5%

 4 months	6	10.5%

 5–6 months	7	12.3%

 7–8 months	9	15.8%

 9–10 months	8	14.0%

 11–12 months	2	3.5%

 13–14 months	6	10.5%

 15–18 months	3	5.3%

 19–22 months	4	7.0%

 23–26 months	3	5.3%


Predisposing factor	Mechanism of action

Moisture [1, 3, 12]	Increased relative moisture of the skinDamage to the skin barrier

Friction [3, 10, 11]	Friction between diaper and damp skin increases skin damage (convex regions)

Urine [1, 3, 9]	Presence of urea causes irritation and is the base product for conversion to ammonia

Feces [1, 3, 9, 13, 20]	The presence of lipases and proteases causes skin damage with filaggrin proteolysis and increased NMFa and TWELb

Ammonia and increased pH [1, 3, 12, 13]	Conversion of urea to ammonium hydroxide by bacterial flora (main responsible, Bacillus ammoniagenes)Increase in pH from 5.5 to 6.8–7.15

Microorganisms [1, 3, 12, 13, 16–19, 21, 22]	BacteriaStaphylococcus aureus (isolated most frequently)Other: (β-hemolytic) Streptococcus sp., E. coli and Bacteroides sp.More than 80 %C. albicans (80−90 %)Other: C. tropicalis, C. parapsilosis, C. glabrata

Use of antibiotics [1, 3, 9, 21, 22]	Use of broad-spectrum antibiotics causes increased Candida spp.

Association with other conditions [1, 3, 11]	Seborrheic dermatitis, inverse psoriasis, epidermolysis bullosa, granuloma gluteale infantum and acrodermatitis enteropathica


Plastid type	Plastid size (μm)	Protein content (pg/plastid)

Chloroplasts (7-days-old light-grown leaves)	3.24 ± 0.23	8.13 ± 1.42

Leucoplasts (4-days-old dark-grown roots)	1.81 ± 0.21	1.85 ± 0.63


Formula	Observations	Grade

F1	Rapidly forming clear emulsion	A

F2	Rapidly forming clear emulsion	A

F3	Rapidly forming clear emulsion	A

F4	Rapidly forming clear emulsion	A

F5	Rapidly forming clear emulsion	A

F6	Rapidly forming clear emulsion	A

F7	Rapidly forming clear emulsion	A

F8	Rapidly forming clear emulsion	A


Primary antibody	Manufacturer (Cat. No.)	Pretreatment	Working dilution

Mouse anti-CD20 monoclonal antibody	Zymed, San Diego, CA, USA (18-0155)	HP CB (pH 6.0)	1:100

Mouse anti-CD79A monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD79α-192)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD3ε monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD3-PS1)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD45RO monoclonal antibody	Zymed, San Diego, CA, USA (08-1365)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD5 monoclonal antibody	Zymed, San Diego, CA, USA (08-1283)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD10 monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD10-270)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD23 monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD23-1B12)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD30 monoclonal antibody	Zymed, San Diego, CA, USA (08-0155)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD56 monoclonal antibody	Zymed, San Diego, CA, USA (08-0152)	HP CB (pH 6.0)	Ready to use

Mouse anti-Bcl-6 monoclonal antibody	Zymed, San Diego, CA, USA (08-1426)	HP EDTA (pH 9.0)	Ready to use

Mouse anti-ALK monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2035)	HP EDTA (pH 8.0)	Ready to use

Mouse anti-Ki-67 monoclonal antibody	Zymed, San Diego, CA, USA (18-0192Z)	HP CB (pH 6.0)	1:50

Mouse anti-TdT monoclonal antibody	Zymed, San Diego, CA, USA (18-7237)	HP EDTA (pH 9.0)	1:50

Mouse anti-TIA-1 monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2183)	HP CB (pH 6.0)	Ready to use

Mouse anti-Perforin monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2118)	HP CB (pH 6.0)	Ready to use

Mouse anti-Granzyme B monoclonal antibody	Newmarket Scientific, Newmarket, Suffolk, UK (MS-1157-s)	HP CB (pH 6.0)	Ready to use

Mouse anti-PD-1 monoclonal antibody	Zymed, San Diego, CA, USA (0381)	HP CB (pH 6.0)	1:100

Goat anti-CXCL13 polyclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100

Mouse anti-CD4 monoclonal antibody	Zymed, San Diego, CA, USA (0032)	HP CB (pH 6.0)	1:200

Rabbit anti-CD8 monoclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100


 	Non-PD	PDa

Gender	Male	Female	Male	Female

Number	10	11	14 	12

Age (years)	70 ± 3.2 	71 ± 3.2	73 ± 2.1	73 ± 2.6

Disease duration (years)	NAb	NA	5.8 ± 0.60	4.8 ± 0.60


The nursing home as my home	Interpersonal care quality

‘Being at home in a nursing home’	‘Care for and alleviation of medical, physical and psychological needs’

‘Paying the price for 24-hour care’	‘Protecting the resident’s integrity’

‘Personal habits and institutional routines’	‘Psychosocial well-being’

‘Meaningful activities for a meaningful day’


District name	Upazila Health Complex (UHC)	Samples (N)	K13 Nested PCR and sequencing N (%)	Non-synonymous Mutation N (%)

Bandarban	Lama UHC	14	149(100)	0(0.0)

Cox’s Bazar	Ramu and Ukhia UHC	74	69(93.2)	0(0.0)

Netrokona	Durgapur and Kalmakanda UHC	10	9(90)	0(0.0)

Mymensingh	Haluaghat UHC	2	2(100)	0(0.0)

Khagrachari	Matiranga UHC	154	144(93.5)	2*(1.29)

Rangamati	Rajasthali UHC	6	5(66.7)	0(0.0)

Moulvibazar	Sreemangal and Kamalganj UHC	11	11(100)	0(0.0)

	Total	271	254(93.7)	2(0.78)


Genomic resources	Source material	Number

Mapping populations

 DH line	Chiffu-401-42 × Kenshin-402-43	78 lines (F2 generation)

 RI line	Chiffu-401-42 × Kenshin-402-43	201 lines (F8 generation)

BAC libraries

 HindIII (KBrH) 	Chiffu-401-42	56592 clones (115 kb(1))

 BamHI (KBrB)	Chiffu-401-42	50688 clones (124 kb(1))

 Sau3AI (KBrS)	Chiffu-401-42	55296 clones (100 kb(1))

cDNA libraries

 22 cDNA libraries	Different tissues of Chiffu-401-42 and Jangwon including leaves, roots, cotyledons, stems,seedlings, ovules, siliques, anthers 	—

BAC-end sequences	KBrH, KBrB, and KBrS clones 	200017 sequences

ESTs	22 cDNA clones 	129928 sequences

BAC shotgun sequences	KBrH, KBrB, and KBrS clones	on-going(2)


Equipment contents of the emergency caesarean section tray	Equipment for neonatal resuscitation and stabilization

Scalpel with no. 10 blade	Overbed warmer

Lower end of Balfour retractor	Neonatal airway supplies

Pack of sponges	Umbilical access

2 Kelly clamps	Medications (e.g., epinephrine 1 : 10 000)

Needle driver

Russian forceps

Sutures and suture scissors


Admitting medical diagnosis 	Number of subjects (total n = 126)

Stroke (all types)	38

General medical (nonbrain)1	23

Brain tumor (all types)	22

Neurological disease (brain)2	20

Orthopedic3	14

Hydrocephalus (all types)	 9


	Female	Male

Succeeded in returning to workplace **	49 (48.0 %)	237 (67.3 %)

Relapse of psychiatric symptoms **	37 (36.3 %)	71 (20.2 %)

Moved to another medical facility	6 (5.9 %)	12 (3.4 %)

Retirement or other	10 (9.8 %)	32 (9.1 %)

Total	102	352


Gene category	List hits	Population hits	EASE score

(GO biological process)	(Total = 348)	(Total = 10,937)

response to external stimulus	67	1263	2.52E-05

 response to biotic stimulus	61	821	6.47E-10

 defense response	57	756	1.62E-09

 immune response	56	682	9.89E-11

 response to pest/pathogen/parasite	27	444	1.92E-03

 antigen processing, endogenous antigen via MHC class I	4	12	5.63E-03

response to stress	37	784	1.57E-02

signal transduction	97	2196	3.43E-04

 intracellular signaling cascade	47	761	1.62E-05

 protein kinase cascade	12	155	1.04E-02

 activation of MAPK	4	16	1.30E-02

phosphate metabolism	33	662	1.13E-02

 phosphorylation	28	524	8.90E-03

 protein amino acid phosphorylation	26	478	9.74E-03

RNA splicing, via transesterification reactions	8	83	1.61E-02


Exogenous variable	Endogenous variable

Arm movement speed (plate tapping)	Agility (10x5m shuttle run)	Explosive strength of the legs (standing broad jump)	Trunk strength (sit-ups)	Explosive strength of trunk and shoulder girdle (1kg medicine ball throw)	MAP	Flexibility (sit and reach)

Body height	−0.677	−0.635	0.638	0.581	0.702	0.309

Body mass		0.302

BMI					0.488		0.233

Rohrer’s index

∑ of skinfold thickness	0.123		−0.437	−0.220	−0.588		−0.455

LBM						0.605

Objective quality of life index		−0.177	0.216			0.114

Subjective quality of life index	0.110			−0.090			0.136

R	0.649	0.494	0.685	0.543	0.727	0.924	0.308

R2	0.422	0.244	0.469	0.295	0.529	0.854	0.095

F	22.620	9.992	27.370	13.002	34.862	181.37	3.255

p	0.000	0.000	0.000	0.000	0.000	0.000	0.025


Mikołajskie september	Mamry september

Microscope	DGGE-ITS	Microscope	DGGE-ITS

taxon	(cells/mL)	taxon	(cells/mL)

Snowella litoralis	3	 	Snowella litoralis	118

Snowella lacustris	31	 	Snowella lacustris	1

 	 	 	Woronichinia compacta	1

 	 	 	Woronichinia naegeliana	2

Chroococcus spp.	<1	 	Chroococcus spp.	13

 	 	 	Aphanothece spp.	779

 	 	 	Microcystis aeruginosa	19	Microcystis

 	 	 	Microcystis flos-aquae	7

 	 	 	Microcystis smithii	5

Aphanocapsa spp.	34	 	Aphanocapsa spp.	4599

Aphanocapsa planctonica	4	 	Aphanocapsa planctonica	75

 	 	 	Coelosphaerium kuetzingianum	2

Coelosphaerium minutissimum	3	 	Coelosphaerium minutissimum	18

 	 	 	Merismopedia punctata	1

Cyanodictyon reticulatum	2

 	 	 	Cyanodictyon cf. planctonicum	7

 	 	 	Lemmermanniella pallida	4

Synechococcus-like/Cyanobium-like	60042	Synechococcus	Synechococcus-like/Cyanobium-like	76386	Synechococcus

Aphanizomenon gracile	839	Aphanizomenon (?)	Aphanizomenon gracile	336	Aphanizomenon (?)

Cuspidothrix issatschenkoi	20	Cuspidothrix issatschenkoi	Cuspidothrix issatschenkoi	25	Cuspidothrix issatschenkoi

 	 	Dolichospermum	Dolichospermum lemmermannii	1	Dolichospermum

 	 	Phormidium (?)	 	 	Phormidium (?)

Planktothrix agardhii	45	Planktothrix	 	 	Planktothrix

Planktothrix suspensa

 	 	Pseudanabaenaceae	 	 	Pseudanabaenaceae

 	 	 	 	 	Leptolyngbya

Limnothrix lauterbornii	128	 	Limnothrix lauterbornii	154

Limnothrix redekei	692	 	Limnothrix redekei	742

Planktolyngbya limnetica	5455	 	Planktolyngbya limnetica	3293

Pseudanabaena catenata	5963	 	Pseudanabaena catenata	1393

Pseudanabaena limnetica	18172	 	Pseudanabaena limnetica	24635

 	 	 	Pseudanabaena mucicola	10

 	 	Romeria (?)	Romeria gracilis	214	Romeria (?)

 	 	unassigned sequences	 	 	unassigned sequences

 	 	nonsequenced	 	 	nonsequenced


 Causes of preterm labor	Spontaneous preterm labor	PROM	Preterm elective termination of pregnancy	Term labor

Group

Case (progesterone)

	Number	0	4	0	48

	Percentage	0%	7.7%	0%	92.3%

Control (placebo)

	Number	3	2	3	39

	Percentage	6.4%	4.3%	6.4%	83%


Dataset	Number	Overlap	P Valuea	Odds Ratio

Expressed genes for Smaug-dependent decay (embryos 2–3 hr)	3956

Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)b	418

Smaug-dependent-miR target genes	1507	151	4.9 × 10−6	1.6

Expressed genes for Smaug-dependent decay (embryos 2–3 hr)	3956

Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)c	341

Smaug-dependent-miR target genes	1507	128	3.1 × 10−6	1.7

Expressed genes for Smaug-RIP (embryos 0–3 hr)	4481

Smaug-RIP genes (embryos 0–3 hr, 5% FDR)	339

Smaug-dependent-miR target genes	1200	101	0.11	1.1


Suspected VOC	Healthy vs. Benign + Cancer	Healthy + Benign vs. Cancer	Cancer vs. DCIS	Triple Negative vs. Other	HER2+ vs. Other	HER2 + status*vs. Other	HER2+ status (Non Luminal) vs. Other	HER2+ status (Luminal) vs. Other

Ethanol	X	X	X			X

Acetone					X		X

Cyclopentane				X

Carbonic acid, dimethyl ester (DMC)					X	X		X

Pentane, 2, 3-dimethyl-			X				X

Heptane		X	X

Toluene						X

Cyclohexane, 1, 4-dimethyl-				X				X

Acetic acid, butyl ester				X

Benzene, 1, 3-dimethyl-					X	X

2-Propenoic acid, butyl ester	X	X

alpha.-Pinene	X				X

5-Hepten-2-one, 6-methyl-		X

1-Hexanol, 2-ethyl-			X

Sensitivity	86	78	70	40	67	68	100	73

Specificity	70	61	83	95	76	72	57	70

Accuracy	83	72	81	87	74	70	82	72

p-value	< 0.0001	< 0.0001	0.0001	0.006	0.0001	< 0.0001	0.0047	0.0018

AUC	0.93	0.79	0.88	0.78	0.83	0.82	0.91	0.87


Clinical manifestations/Hospitalization	Number of events	Number of doses per event	Rate per 10,000 dosesb

Local

	Pain	189	4,040	2.5

	Nodule	163	4,684	2.1

	Abscess	33	23,138	0.4

	Lymphadenitis	33	23,138	0.4

	Ulcer	1	763,548	0.1

Systemic

	Headache	1	763,548	0.1

	Nausea	10	76,355	0.1

	Diarrhea	23	33,198	0.3

	Vomiting	54	14,140	0.7

	Cyanosis	27	28,280	0.4

	Malaise	23	33,198	0.3

	Irritability	102	7,486	1.3

	Sleepiness	44	17,353	0.6

	Myalgia	7	109,078	0.1

	Exanthema	46	16,599	0.6

	Jaundice	1	763,548	0.1

	Parotitis	20	38,177	0.3

	Fever	344	2,220	4.5

	< 38°C	51	14,971	0.7

	38|-|39,4°C	196	3,896	2,6

	≥ 39.5°C	68	11,229	0.9

	Hypotonic-hyporesponsive episode	67	11,396	0.9

	Adenoiditis	18	42,419	0.2

	Arthralgia	1	763,548	0.1

	Hypersensitivity	11	69,413	0.1

	Seizure	25	30,542	0.3

	Loss of consciousness	6	127,258	0.1

	Myelitis	1	763,548	0.1

	Paresis	1	763,548	0.1

Hospitalization	16	47,722	0.2


		Strain	NRRL2338	Px

COG	Functional categories	% COG probesets	% Probesets with q-value < = 0.001	% Probesets with q-value < = 0.001

I	Cellular processes and signaling

I.1	Cell cycle control, cell division, chromosome partitioning	0,35	0,99	0,69

I.2	Cell motility	0,01	0	0

I.3	Cell wall/membrane/envelope biogenesis	2,05	3,22	3,81

I.4	Defense mechanisms	0,89	0,00	0,87

I.5	Intracellular trafficking, secretion, and vesicular transport	0,24	0,25	0,69

I.6	Posttranslational modification, protein turnover, chaperones	1,90	5,94	3,99

I.7	Signal transduction mechanisms	1,91	0,99	1,91

II	Information storage and processing

II.1	Amino acid transport and metabolism	0,01	0	0

II.2	Cell wall/membrane/envelope biogenesis	0,01	0	0

II.3	Chromatin structure and dynamics	0,01	0	0

II.4	General function prediction only	0,30	0,50	0,35

II.5	Nucleotide transport and metabolism	0,07	0	0

II.6	Posttranslational modification, protein turnover, chaperone	0,04	0	0

II.7	Replication, recombination and repair	2,44	0,74	2,43

II.8	RNA processing and modification	0,01	0

II.9	Secondary metabolites biosynthesis, transport catabolism	0,04	0

II.10	Signal transduction mechanisms	0,71	0,50	0,69

II.11	Transcription	7,20	2,23	3,29

II.12	Translation, ribosomal structure and biogenesis	2,48	4,21	10,75

III	Metabolism

III.l	Amino acid transport and metabolism	6,60	0	8,15

III.2	Carbohydrate transport and metabolism	6,08	7,67	6,59

III.3	Cell wall/membrane/envelope biogenesis	0,38	0	0,17

III.4	Coenzyme transport and metabolism	2,63	5,20	4,33

III.5	Energy production and conversion	4,79	9,90	8,15

III.6	Inorganic ion transport and metabolism	2,68	4,21	2,25

III.7	Lipid transport and metabolism	4,24	2,72	5,03

III.8	Nucleotide transport and metabolism	1,27	2,97	3,64

III.9	Posttranslational modification, protein turnover, chaperones	0,08	0	0,17

III.10	Secondary metabolites biosynthesis, transport catabolism	2,90	2,48	2,77

III. 11	Signal transduction mechanisms	0,16	0	0

IV	Poorly characterized

IV.1	Function unknown	32,11	27,23	22,70

IV.2	General function prediction only	7,37	8,17	6,59

	Total probesets	7060	404	577


No.	Name	Concentration of β-asarone (mg/kg)	Concentration of α-asarone (mg/kg)	Source

1	Product 1	Not detected	Not detected	–

2	Product 2	Not detected	Not detected	–

3	Product 3	273.6 ± 21.6	40 ± 1.2	Acori tatarinowii Rhizoma

4	Product 4	Not detected	Not detected	–

5	Product 5	230.9 ± 21.3	34.7 ± 1.2	Acori tatarinowii Rhizoma

6	Product 6	4.8 ± 0.2	5.0 ± 0.2	Acori tatarinowii Rhizoma

7	Product 7	11.2 ± 0.1	47.7 ± 3.0	Acori graminei Rhizoma

8	Product 8	181.6 ± 5.4	106.1 ± 1.0	–

9	Product 9	Not detected	Not detected	–

10	Product 10	Not detected	Not detected	–

11	Product 11	181.6 ± 5.4	106.1 ± 1.0	unknown source

12	Product 12	4.3 ± 0.3	13.3 ± 0.1	unknown source

13	Product 13	3.2 ± 0.2	10.9 ± 3.3	Asari radix et Rhizoma

14	Product 14	241.5 ± 10.5	53.2 ± 1.2	unknown source

15	Product 15	Not detected	Not detected	–

16	Product 16	Not detected	Not detected	–

17	Product 17	Not detected	Not detected	–

18	Product 18	243.5 ± 18.2	144.3 ± 7.1	unknown source

19	Product 19	Not detected	Not detected	–

20	Product 20	425.7 ± 28.2	62.8 ± 3.1	Acori tatarinowii Rhizoma

21	Authentic herb Acori tatarinowii	7679.8 ± 85.7	679.1 ± 20.3	Acori tatarinowii Rhizoma


Characteristic	Patients with asthma	Patients without asthma	P-Value*

 	No. (%) (n = 137)	No. (%) (n = 336)

Tachypnea	60/137 (44)	110/336 (33)	0.07

Tachycardia	88/137 (64)	213/336 (63)	0.86

Intensive care unit admission	37/133 (28)	108/321 (34)	0.31

Mechanical ventilation	16/127 (13)	69/301 (23)	0.02

Acute respiratory distress syndrome	9/129 (7)	38/292 (13)	0.10

Sepsis syndrome	7/128 (6)	31/291 (11)	0.12

Death	5/137 (4)	32/332 (10)	0.04

Influenza antiviral agent receipt

 Any during hospitalization	101/137 (74)	270/336 (80)	0.15

 ≤ 2 days of illness onset	49/99 (50)	106/269 (39)	0.10

 ≤ 2 days of admission	79/92 (86)	219/253 (87)	0.87

 Median days from illness onset to antiviral initiation (range)	3 (0 – 18)	3 (0 – 32)	0.06

Other treatment

 Antibiotics	101/137 (74)	260/336 (77)	0.40

 Steroids	83/137 (61)	96/336 (29)	<0.01


Treatment priority	Probability

0	0.1

1	0.2

2	0.3

3	0.4